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Growth hormone (GH) effects growth and contributes to a lean phenotype in 
broiler chickens. GH secretion by the anterior pituitary begins on embryonic day (e) 
14, concomitantly with a rise in adrenal glucocorticoids (GC) or corticosterone 
(CORT) secretion. CORT treatment of chicken embryonic pituitary (CEP) cells 
induces GH secretion prematurely. GC induction of the GH gene requires on-going 
protein synthesis or an intermediary protein, but the gene lacks a classical GC-
response element. We hypothesized that a GC-responsive intermediary protein is 
necessary for the CORT induced increase in GH. Characterization of the upstream 
region of the gene may help identify such a protein. To this end, a fragment of the GH 
gene (-1727/+48) was cloned into a luciferase reporter and characterized in e11 CEP 
cells. CORT treatment increased luciferase activity and mRNA. Inclusion of CHX 
blocked CORT induction of luciferase mRNA. Through deletion analysis, we found 
  
that a GC-responsive region (GCRR) is located at -1045 to -954. By defining the GC-
responsive region and cis-acting elements located within, trans-acting proteins 
involved in GC induction of the GH gene may be identified. The GCRR is CORT-
responsive in either orientation, but it is context-dependent. Potential transcription 
factor motifs in the GCRR include ETS-1 and a degenerate GRE (GREF). Nuclear 
proteins bound to a GCRR probe in a CORT-regulated manner and unlabeled 
competitor DNA competed off binding. Mutation of the central portion of the DNA 
probe resulted in a significant decrease in protein binding. Mutation of the ETS-1 site 
or GREF site in the -1045/+48 GH construct resulted in ablation of luciferase activity. 
ETS-1 and GR are associated with the endogenous gene under basal and 1.5 h CORT-
treated conditions, while GR recruitment increased after CORT treatment. GC 
regulation of the GH gene during chicken embryonic development requires cis-acting 
elements located 1 kb upstream from the transcription start site and includes 
recruitment of ETS-1 and GR. This is the first study to demonstrate involvement of 
ETS-1 in GC regulation of the GH gene during embryonic development. 
Characterization of GC regulation of the GH gene during embryonic development 
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Chapter 1: Literature Review 
 
Introduction 
Growth hormone (GH) is a protein hormone produced in the anterior pituitary 
(Giustina & Veldhuis, 1998). The pituitary is composed of two lobes: anterior and 
posterior, also known as the adenohypophysis and the neurohypophysis, respectively. 
The anterior pituitary can be considered the master regulator of homeostasis because it 
contains five different cell types that secrete hormones which are essential for growth, 
reproduction, and metabolism in vertebrates. GH is produced by the somatotroph cell 
type, and has several important functions in the body, most notably, bone and muscle 
growth, muscle accretion, lipolysis, and promotion of immune function (Fig. 1). It is 
under strict regulation at the gene, mRNA, and protein levels, through feedback loops 
from the hypothalamus, liver, adrenal glands, and thyroid gland (Giustina & Veldhuis, 
1998). Understanding of the regulation of GH will aid in the overall understanding of 
growth and metabolism in vertebrates. Major regulators of the GH gene include the 
pituitary specific factor, Pit-1, glucocorticoids, thyroid hormone, specificity protein 1 
(Sp1), and cAMP response element binding protein (CREB). Pit-1 is necessary for the 
differentiation of somatotrophs during development, but it is not sufficient. Other 
transcription factors are necessary for the final induction of the GH gene in all species; 
however, the necessary transcription factor(s) and their associated upstream signaling 
pathways have not been fully elucidated. Most species studied, such as mouse, rat, dog, 






Figure 1: Functions of GH. GH is produced in the anterior pituitary gland and directly effects long bone 
growth. It travels to the liver to induce secretion of insulin-like growth factor 1 to effect overall body 




of 5 related genes, and these genes are under the control of a locus control region (LCR) 
that directs tissue-specific expression. It is important to highlight the species-specific 
similarities and differences in the regulation of the GH gene, as this may lead to the 
discovery of the unknown necessary differentiating transcription factors. The review here 
will focus on pituitary development, GH gene regulation, glucocorticoid mechanism of 
action, and glucocorticoid regulation of the GH gene.  
Anterior Pituitary Development 
Introduction 
In the brain, the pituitary resides ventral to the hypothalamus in the sella turcica 
and is connected to the hypothalamus through the highly vascularized hypophyseal stalk. 
Hormones produced in the hypothalamus are released into the stalk and are quickly 
transported to the pituitary via a portal blood system. All of the hormones produced by 
the pituitary are controlled by hormones produced in the hypothalamus. GH is positively 
regulated by growth hormone-releasing hormone (GHRH) and negatively regulated by 
somatostatin (SRIF), both of which are produced in nuclei within the hypothalamus 
(Anderson et al., 2004).  
The pituitary is a classical neuroendocrine organ of both neural and ectoderm 
origin necessary for the maintenance of homeostasis, metabolism, reproduction, growth 
and lactation. The anterior pituitary is composed of five distinct cell types: corticotrophs, 
gonadotrophs, thyrotrophs, somatotrophs and lactotrophs. The cell types are classified 
based on the primary hormone that each one produces. Corticotrophs secrete 
adrenocorticotropin (ACTH), gonadotrophs secrete luteinizing hormone and follicle-
stimulating hormone, thyrotrophs secrete thyroid-stimulating hormone, and lactotrophs 
 5 
 
secrete prolactin. Each of these cell types arise from a single primordial cell and is 
classified based on the type of hormone that is produced by the cell (Griffen & Ojeda, 
2004).The pituitary originates as a structure known as Rathke’s pouch. It is composed of 
two distinct parts: the neurohypophysis and the adenohypophysis or the posterior and 
anterior pituitary, respectively (Griffen & Ojeda, 2004). Discussion of the pituitary will 
be limited to only the anterior pituitary.  
Formation of Rathke’s pouch begins as the cells of the forebrain (ventral 
diencephalon) grow and displace cells of the anterior neural ridge (ANR). 
Simultaneously, an evagination from the roof of the pharynx (oral ectoderm) pushes 
dorsally into the displaced cells of the ANR. The cells of the ANR then thicken and 
invaginate to form Rathke’s pouch (Figure 2A) (Griffen & Ojeda, 2004). Pituitary 
organogenesis can be divided into four phases: formation of Rathke’s pouch, cell 
proliferation and zone partitioning, cell fate determination and terminal differentiation 
(Figure 2B). 
 Cell proliferation and zone partitioning are regulated by both extrinsic and 
intrinsic signals. Extrinsic signals regulating organogenesis include fibroblast growth 
factors (FGF), bone morphogenetic proteins (BMP), members of the Wnt gene family, 
and Sonic hedgehog (Shh) (Zhu et al., 2003). The former three originate from the ventral 
diencephalon, whereas Shh emanates from the oral ectoderm (Figure 2C). It seems that 
FGF8 and BMP4 are required for initial organ commitment, proliferation and progression 
(Treier et al., 1998). FGF8 induces Lhx3/P-LIM, a LIM homeodomain transcription 
factor, so that development of the pituitary will continue past the formation of Rathke’s 




Figure 2: The anterior pituitary gland is formed from Rathke’s pouch. A) Rathke’s pouch is derived from 
the oral ectoderm and the ventral diencephalon. B) There are four phases of development of the anterior 
pituitary gland. C) The differentiation of cell types requires the activation of specific transcription factors in 
a spatially and temporally regulated manner. D) Ontogeny of the cell types in the chicken anterior pituitary 
gland during embryonic development. E) Localization of the cell types in the anterior pituitary gland of the 
adult chicken.   
 7 
 
 type II results in failure of the organ to proliferate and causes rapid apoptosis 
immediately following the formation of Rathke’s pouch. Deletion of BMP4 causes 
embryonic death at roughly E10 and failure of invagination of Rathke’s pouch (Olson et 
al., 2003). Shh localizes throughout the oral ectoderm but is entirely absent from the 
invaginating Rathke’s pouch. Shh is required for pituitary proliferation and patterning 
after E10 and works with FGF8 to sustain ventral expression of Lhx3 (Treier et al., 
1998). This cooperativity is similar in limb and neural tube development. Intrinsic 
signaling or signals originating from Rathke’s pouch include BMP2 and Wnt4. Inhibition 
of BMP2 causes loss of the thyrotrophs, somatotrophs, and lactotrophs, but not 
corticotrophs. Attenuation of the BMP signal is also required for terminal differentiation 
of the cell types. Cell types are arranged positionally within the gland’s proliferation 
zones, due to gradient signaling patterns of FGF8, BMP, Wnt and Shh. Thus, 
somatotrophs and lactotrophs arise caudo-medially, gonadotrophs are positioned more 
rostro-ventrally and corticotrophs are ventrally positioned in the mouse (Olson et al., 
2003).  
The gradient signaling patterns described above result in the induction of 
transcription factors in spatially overlapping patterns. The transcription factors are 
generally from the homeodomain class, such as the LIM, paired-like, bicoid-like and 
sine-oculus families. Multiple members of the LIM family: Lhx3, Lhx4, Lhx2 and Isl-1, 
are expressed throughout Rathke’s pouch during pituitary development, however, a 
specific causal relationship between the LIM family and cell lineage has yet to be 
established (Zhu et al., 2007). Paired-like homeodomain factors exert opposing 
activator/repressor functions, as each binds to similar DNA sequence elements and can 
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heterodimerize with its cognate paired factor. Rpx/Hesx1 is expressed early in pituitary 
development and appears to be necessary for early proliferation and progression of the 
gland. It can heterodimerize with Prophet of Pit-1 (Prop-1) and can inhibit the activation 
properties of the Prop-1 gene (Zhu et al., 2007). Prop-1 is necessary for the development 
of three cell types: thyrotrophs, somatotrophs, and lactotrophs. Down regulation of 
Rpx/Hesx1 occurs when it interacts with and is sequestered by a member of the 
groucho/transducin-like enhancer of split family (TLE). Down regulation of Rpx/Hesx1 
is necessary to allow Prop-1 to exert its effects on cell lineage and proliferation (Olson et 
al., 2003). Pax6, another homeodomain regulator, is necessary to modulate ventral/dorsal 
determination. Pax6 mutant mice have an increased number of ventral thyrotrophs and 
gonadotrophs and a decreased number of dorsal somatotrophs and lactotrophs. Pitx1 and 
Pitx2, bicoid-related homeodomain factors, are necessary for the development of lung 
asymmetry, cardiac positioning and tooth morphogenesis, besides the pituitary (Lin et al., 
1999). Deletion of Pitx1 results in the diminished expression of the gonadotrophs and 
thyrotrophs and increased expression of the POMC gene (Zhu et al., 2007). Pitx2 
knockout mice exhibit pituitary arrest at e10.5, as well as defects in tooth development, 
ventral body wall closure and right lung isomerism (Olson et al., 2003). Pitx1 and Pitx2 
are necessary for the development of multiple organs and processes and are not specific 
to pituitary organogenesis. 
The aforementioned factors are required for cell proliferation and partitioning of 
the pituitary organ; but what regulates the differentiation of the distinct cell types, and 
further, what regulates hormone production, namely GH, within the cell type? It is 
important to study the transcription factors necessary for the development of the pituitary 
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gland, in order to determine if these same transcription factors or different factors are 
necessary for the terminal differentiation of hormone-secreting cells. Some distinct 
transcription factors that are necessary for terminal differentiation of distinct cell types 
have already been discovered. Pit-1 (Pituitary specific factor-1) is responsible for the 
terminal differentiation of somatotrophs and lactotrophs. Pit-1 and GATA2 are the 
necessary factors for thyrotrophs. GATA2, SF-1 and Egr-1 are necessary for 
differentiation of gonadotrophs, while T-pit and possibly STAT3 are involved in the 
differentiation of corticotrophs (Lamolet et al., 2001 & Pulchino et al., 2003). Clearly, 
distinct combinations of transcription factors are necessary for the terminal differentiation 
of hormone-secreting cell types. The GH gene may require a unique combination of 
transcription factors for activation. 
In rats, αGSU producing cells first appear on e11.5, ACTH-producing cells first 
appear on e14.5, followed by TSH-producing cells on e15, LH-producing cells on e16.5, 
and FSH-producing cells on e17 (Simmons et al., 1990). GH-producing cells begin to 
appear on e18, with a moderate increase on e20. GH is detected in circulation on e19 
(Setalo & Nakane, 1976; Chatelain et al., 1979; Watanabe & Daikoku, 1979). In the 
chicken, a pit-1 independent population of thyrotrophs appears on e5, corticotrophs are 
the next cell type to emerge on e7. A pit-1 dependent population of thyrotrophs emerge 
on e9 followed by gonadotrophs between e10-e12. Then somatotrophs differentiate 
around e12 and become a significant population of the gland between e14 and e16 (Porter 
et al, 1997). Last, lactotrophs differentiate around e18 (Parkinson et al., 2010) (Figure 
2D). In the mouse, thyrotrophs first appear on e12.5 in the rostral tip of the gland, 
although this cell population is Pit-1 independent.  Pit-1-dependent populations of 
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thyrotrophs emerge at e14.5 in the caudomedial region (Lin et al, 1994). In mice, GH-
producing cells first appear on e15 and the population increases rapidly on e16 (Dole et 
al., 1990). In the chicken anterior pituitary gland, corticotrophs are localized ventrally 
throughout. Gonadotrophs are localized throughout the entire gland, while lactotrophs are 
restricted to the cephalic lobe. In contrast, somatotrophs and thyrotrophs are localized to 
the caudal lobe (Figure 2E) (Parkinson et al., 2010). 
 
The Role of Pit-1 in Anterior Pituitary Development and Somatotroph Differentiation 
Differentiation of a pituitary cell type is complete once production of its hormone 
is initiated. Many known and unknown factors are necessary for the complete 
differentiation of hormone-secreting pituitary cells, and somatotrophs in particular. Pit-1, 
also known as GHF-1, is necessary for the differentiation of a lineage of cell types: 
thyrotrophs, somatotrophs and lactotrophs (Anderson & Rosenfeld, 1994). But how does 
one gene/one protein induce the expression of a specific hormone in one cell type and 
exclude the same expression in other cell types? For example, GH is secreted in 
somatotrophs and although the gene is present in lactotrophs and thyrotrophs, it is not 
secreted. 
Pit-1 belongs to the POU family of transcription factors that includes Pit-1, Oct-1 
and Oct-2, and Unc-86 (Van As et al., 2000). These highly conserved transcription 
factors each have a homeodomain that is linked to another domain known as the POU-
specific domain. Most other family members are highly expressed in the nervous system. 
Pit-1 was first discovered as the transcription factor that is necessary for the expression of 
growth hormone and prolactin, and this definition was later extended to include thyroid 
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stimulating hormone β, or TSHβ (Nelson et al., 1988).  The proximal 320 bp of the 
human GH gene promoter is necessary and sufficient for selective expression of the GH 
gene in mouse pituitary. This region contains multiple Pit-1 sites and a thyroid hormone 
response element. Prolactin has a similar promoter region of 3 kb with multiple Pit-1 sites 
and an estrogen-regulated Pit-1 dependent enhancer as well (Crenshaw et al 1989; Lira et 
al, 1988). Although Pit-1 is required for normal somatotroph differentiation, it is not the 
final differentiating factor because it is expressed before GH expression and in two other 
distinct hormone-secreting cell types. In the rat, Pit-1 containing cells begin to emerge on 
e15.5 and become significant at e16.5 (Simmons et al., 1990). In the mouse, Pit-1 
containing cells emerge on e13.5 (DiMattia et al., 1997). In the chicken, Pit-1 is 
expressed on e8 (Tanaka et al., 1999). 
Pit-1 contains a bipartite DNA binding domain that resembles the classic helix-
turn-helix motif that is necessary to bind in the double helix major groove. Further, both 
the homeodomain and POU specific domain are required for high affinity binding to 
DNA sequences. The first published Pit-1 binding site was TATNCAT, and it requires an 
AT-rich sequence immediately 5’ to the consensus (Fox et al., 1990). A more recent 
publication denotes this consensus sequence: 5’-(T/A)NCTNCAT-3’ (Ohkubo et al, 
1996). The highly conserved Pit-1 sites in the human GH gene are -127/-107 
(AGCTTCTAAATTATCCATTA) and -87/-72 (CCATGCATAAATGTA) (Nelson et al, 
1988). In the chicken, a Pit-1 site was discovered at -113/-104 with a sequence of 
ATCTGCAT (Ip et al. 2004). However, the teleost/avian consensus sequence is 5’-
(T/A)NCTNNCAT-3’. Interestingly, the spacing between the two sites, consensus and 
AT-rich, determines the outcome of expression for the corresponding gene. Depending 
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on the binding site, Pit-1 will induce expression of GH and suppress prolactin in 
somatotrophs, while the opposite is observed in lactotrophs (Nelson et al., 1998).  
Pit-1 is necessary for the terminal differentiation of thyrotrophs. Thyrotrophs 
produce thyroid-stimulating hormone (TSH), which is composed of a common subunit 
(αGSU) shared by gonadotropins and a β subunit unique to the thyrotroph cell type. Pit-1 
and another factor, GATA-2, bind to specific sequence elements upstream of thyrotroph-
specific genes in order for activation (Umeoka et al., 2002). Simultaneously, GATA-2 
and Pit-1 can heterodimerize so that GATA-2 is unable to bind to upstream sequence 
elements of gonadotroph-specific genes, thus ensuring that gonadotroph-specific genes 
are not activated in cells destined to the thyrotroph cell fate. Conversely, GATA-2 
binding upstream of gonadotroph-specific genes without Pit-1 blocking allows for the 
terminal differentiation of gonadotrophs and the repression of thyrotroph-specific genes 
(Gordon et al., 1997).  
The question remains, what is the final differentiation factor in somatotroph 
development? It is most likely not Pit-1, since microarray analysis of chicken embryonic 
pituitary glands during development shows no change in Pit-1 expression between e10 
and e17 (Ellestad et al, 2005), and Pit-1 mRNA and protein are not increased by 
treatment with CORT (Fu et al., 2004).   
Growth Hormone: Mechanisms, Actions and Implications 
Growth Hormone (GH) 
In the chicken, GH is a protein hormone composed of 221 amino acids; gh gene 
has five exons and it is located on chromosome 27 (Tuggle & Trenkle, 1996). In most 
mammals, GH is a single gene (Page et al., 1981); however, in primates, GH is a gene 
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locus with six genes (Tuggle & Trenkle, 1996). Pituitary GH is regulated by GH-
releasing hormone, a 44-amino acid peptide produced in the hypothalamus, and 
somatostatin, a 14-amino acid peptide also produced in the hypothalamus (Griffen & 
Ojeda, 2004). The two peptides regulate GH through their cognate G-protein coupled 
receptors (GPCR). Regulation also occurs in a classical negative feedback manner via 
hepatic insulin-like growth factor I (IGF-I). Basal expression of GH is controlled by 
specificity protein 1 (Sp1), NF-1/AP-2, USF and zinc finger 15 (ZN-15). Factors that 
stimulate GH secretion include thyroid hormone, glucocorticoids, retinoic acid, and 
cAMP (Tuggle & Trenkle, 1996). GH is most notably known for directly increasing long 
bone growth and muscle accretion during development (Tuggle & Trenkle, 1996). In the 
embryonic chicken, plasma GH can be detected at e17 (Harvey et al, 1979). The receptor 
for GH is a single-transmembrane-domain, membrane-anchored receptor belonging to the 
cytokine receptor super-family (Griffen & Ojeda, 2004).  
  
Regulation of Transcription of the Growth Hormone Gene: Promoter Analysis 
Growth hormone is predominantly expressed in the anterior pituitary gland. It is 
also expressed in the mammary gland, lymphoid cells, eye, lung, and testes (Harvey et 
al., 1996; 2001). A different set of genes is activated in each of these tissues, resulting in 
a different protein milieu. In the pituitary gland, GH expression is predominantly 
stimulated by glucocorticoids, while in the mammary gland GH expression is 
predominantly stimulated by progestins (Mol et al., 2000).  
The first studies elucidating transcription factors directing GH gene expression 
involved mapping DNaseI hypersensitive sites (HS) also known as DNA footprinting. 
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DNase I is an enzyme that degrades DNA. DNA can only be degraded if it is exposed or 
not covered by proteins. By treating chromatin (DNA bound with proteins) with DNase I, 
base pairs that are covered or protected by proteins can be mapped by sequencing. The 
human GH gene has four DNase I hypersensitive sites (Jones et al., 1995). HS sites I and 
II were later found to be necessary for GH gene expression (Bennani-Baiti et al., 1998). 
FPIII contains binding sites for two factors, one of which was found to be upstream 
stimulating factor (Lemaigne et al., 1989). The protein that caused FPIV was later found 
to be Sp1. The binding activities of Sp1 and Pit-1 to the distal site were mutually 
exclusive and cooperative (Lemaigne et al., 1990). However, Sp1 binding to its site alone 
could not direct transcription of the GH gene.  
Analysis of the canine GH promoter showed several shared binding sites with the 
human, mouse and rat GH genes, including binding sites for Pit-1, progesterone receptor 
(PR), glucocorticoid receptor (GR), Sp1 and ETS1, as well as lymphoid-specific 
transcription factors, such as Ikaros and Pax5 (Lantinga-van Leeuwen et al., 2002). 
Likewise, the mouse GH promoter showed high homology with the rat promoter but 
conservation with pig, cow, and human of only the proximal promoter (Das et al., 1995). 
Comparison of the proximal promoters of the GH gene of the chicken, rat, mouse, and 
human show remarkable similarities (Figure 3). 
Initial studies using transgenics demonstrated a minimal promoter necessary to 
direct GH gene expression to the anterior pituitary gland. This was done mostly in mouse 
oocytes using the human and rat GH genes (Lira et al., 1988). Using the upstream region 
of the rat GH gene fused to the human GH coding sequence injected into fertilized mouse 




Figure 3: Schematic of the proximal promoter of the GH gene from four different species. The proximal 
promoter is relatively conserved, with respect to three transcription factors, Sp1, Pit-1 and CREB.  
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direct expression to the pituitary gland. Using immunohistochemistry, the cells 
expressing the transgene also expressed predominantly GH, but to a lesser extent, 
thyrotropin and prolactin (Lira et., 1988). This site was later found to be the Pit-1 
proximal binding site. 
How, then, does one begin to distinguish between potential transcription factor 
binding sites in the 5’ flanking region of the chicken GH gene and determine the 
availability of transcription factor proteins present in anterior pituitary cells during the 
mid-stage of embryonic development? More specifically, what is the differentiating 
factor for initial GH expression in the anterior pituitary gland of the developing chicken 
embryo? What regulates GH transcription? 
Even though it is well known that Pit-1 directs expression of three cell lineages in 
the pituitary, many studies are centered on potential Pit-1 interacting partners or nearby 
promoter elements in order to discover the cell-specific terminal differentiation factors. 
For example, expression of the Chinook salmon GH gene is controlled by two cAMP 
response elements (CRE) and Pit-1 (Wong et al., 1996). The yellowtail GH gene was also 
cloned, and the promoter was analyzed. A sequence similar, but not identical, to the 
mammalian Pit-1 binding site was found to reside at -128 to -90, which is the same 
location as the mammalian Pit-1 binding site (Ohkubo et al., 1996). Further analysis 
showed that this is the conserved Pit-1 binding site found in avian and teleost species. 
Analysis of evolutionary conserved sequences identified a conserved element located 
between the proximal and distal Pit-1 binding sites. This element was shown to bind a 
zinc finger protein, Zn-15 (Lipkin et al., 1993).  Mutation of the Zn-15 binding site 
decreased hGH expression more than 100 fold. (Lipkin et al., 1993). Therefore, 
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inspection of sequence flanking the Pit-1 site in the chicken GH gene could provide clues 
to the trans-activating factor required in the CORT induction of GH. 
Pit-1 is a homeodomain transcription factor, but there are many other classes of 
transcription factors. One such class is the nuclear hormone receptor which can be 
considered as ligand-activated transcription factors. Nuclear hormone receptors bind 
ligands such as thyroid hormone, glucocorticoid, mineralocorticoid, retinoic acid, 
estrogens, progesterone and androgen (Griffen & Ojeda, 2004). Each of these nuclear 
hormone receptors has their own specific response element. Most studies focus on 
identifying such response elements in the 5’ flanking region of the gene; lower 
eukaryotes have conserved regulatory elements in the 3’ or downstream flanking region. 
Rarely, do regulatory sequences occur within the coding region of a gene. However, a 
GRE has been found in intron 1 of the human GH gene (Slater et al., 1985). Almost 3 kb 
of the human GH gene, including 500 bp each of the 5’flanking region and the 3’ 
flanking region was analyzed for CORT-regulated protein binding. It was found that the 
GH gene contains two glucocorticoid response elements (GRE): one in the upstream 
region and one in the first intron. Further, only the GRE in the first intron produced a 
“footprint” or a DNase I hypersensitive site (Slater et al., 1985). Identification of the 
factor involved in the CORT induction of the chicken GH gene could be accomplished by 
exploring regulatory sequences for potential response elements. 
Analysis and comparison of promoters across species is necessary to determine 
trans-acting factors. A comparison of the GH gene across species allowed for some 
insight into speciation and divergence, adding support to the theory that sequence 
variation is the basis for functional complexity (Buggiotti & Primmer, 2005). This theory 
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more appropriately fits the description of a gene promoter: complexity and variation 
allows for tissue- and time-specific expression of a particular gene. 
Long Range Control: the Human GH gene and its Locus Control Region 
Classical molecular biological and genetic studies typically focus on the 
immediate flanking DNA regions of a gene of interest. There is also evidence that genes 
are under long distance control. A region of DNA located as far as 30 kb away from the 
transcription start site of the gene of interest has been shown to regulate the gene. This 
region is known as a “locus control region” or LCR. 
DNase I hypersensitive site mapping also revealed the presence of a LCR for the 
human GH gene (Jones et al., 1995). The LCR is located between -14 kb and -30 kb 
upstream of the transcription start site of the GH gene. It is thought that this region exists 
because the human GH gene locus actually contains a cluster of five related GH genes 
(hGH-N,  hGH-V, hCS-A, hCS-B and hCS-L). The LCR was originally discovered in the 
β-globin set of genes in the human (Grosveld et al., 1987). The GH gene is 
predominantly expressed in the pituitary, while the chorionic somatomammotropin (CS) 
gene is expressed in the placenta (Jones et al., 1995). The LCR is necessary for human 
GH expression in mouse pituitary. The minimal essential region of the LCR is between -
14.6 kb to -16.2 kb and is necessary to direct human GH expression in the anterior 
pituitary of the embryonic mouse at the appropriate developmental times (Bennani-Baiti 
et al., 1998). Pit-1 is essential for the coordinated transcriptional control of the hGH gene 
cluster (Shewchuk et al., 1999). Pit-1 binding in the HS I and HS II sites is necessary and 
sufficient to direct regulated tissue-specific expression, more so than binding at the 
promoter of the hGH-N gene (Shewchuk et al., 2002). Control of the specified set of 
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genes via the LCR is coordinated through the formation of domains of histone 
modifications (hyperacetylation or methylation) and chromatin looping (Kimura et al., 
2004, Yoo et al., 2006 & Ho et al., 2008). There is also evidence that ongoing non-coding 
transcription of the CD79b gene is essential for regulation by the LCR (Ho et al., 2006). 
The continuous non-coding transcription of the nearby gene, CD79b, allows for the 
constant presence of RNA polymerase II (RNA pol II) and an open chromatin 
conformation. The regulated transcription of the growth hormone gene cluster begins 
with Pit-1 binding at HS-I and in the promoter of the hGH-N gene which then triggers an 
interaction between the two regions accomplished by looping. The looping of the 
chromatin allows for the juxtaposition of the hGH-N promoter into a region of high 
transcriptional activity, the LCR/CD79b transcriptional domain that is dense with RNA 
pol II (Ho et al., 2008).  To this date, a similar LCR has not been identified in the GH 
gene of chicken, mouse or rat, although only one GH gene exists in these species. Rather, 
an LCR is used to direct expression of a group of related genes and non-primates have a 
single GH gene.  
The Connection between Signaling Pathways and Transcription Factors 
Characterizing gene regulation by searching for transcription factor binding sites 
is only half of the story. Transcription factors can also be the end points of cytoplasmic 
signaling pathways, such as kinase cascades. One example is the luteinizing hormone 
receptor (LHR) gene. The LHR gene is induced by the PI3K/PKC signaling pathway and 
Sp1 (Liao et al., 2008). Phorbol myristyl acetate (PMA) activates PKCα and enhances 
Sp1 phosphorylation. Sp1 is also a downstream target of ERK. Once this signaling 
cascade is activated, the HDAC/Sin3A repressor complex is released from the Sp1 site 
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upstream from the LHR gene, histone H3 is acetylated, Sp1 binds to its response element 
and TATA binding protein (TBP) and RNA polymerase II are recruited (Liao et al., 
2008). Elucidating transcriptional regulation should conclude by analyzing whether a 
specific activated transcription factor recruits TBP and RNA polymerase II.  
 
Analysis of Mutant Phenotypes is Necessary for Understanding 
Dwarfism, which usually results from low or no levels of circulating GH or a 
mutation in the GH receptor, has been linked to defects in four other genes to date: Pit-1, 
GHRH-receptor, CREB, and lysine demethylase 1 (LSD1).  
Defects in the Pit-1 gene result in the absence of three hormones (GH, TSH, and 
PRL) and this condition has been characterized as the Snell dwarf mouse (Li et al, 1990). 
Similarly in humans, defects in the Pit-1 gene result in congenital hypothyroidism, 
dwarfism and prolactin deficiency. The little mouse has been found to have a mutation in 
the GHRH-receptor (GHRH-R), thus demonstrating that the receptor for the 
hypothalamic regulatory hormone, GHRH, also plays a role in somatotroph 
differentiation (Godfrey et al, 1993). Dwarf phenotypes in chickens have also been linked 
to mutations in the GH receptor gene (Burnside et al., 1991 & 1992). 
Another study showed that cAMP response element-binding protein (CREB) is 
essential for normal growth. CREB was one of the first transcription factors identified 
that regulates GH gene expression. Over-expression of a dominant negative form of 
CREB in the anterior pituitary resulted in the loss of somatotrophs, low GH levels and 
dwarfism (Struthers et al., 1991). A follow-up study showed that loss of CREB in the 
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brain but not the pituitary also resulted in the same dwarf phenotype (Mantamadiotis et 
al., 2006). 
LSD1 knockout is embryonic lethal. But pituitary-specific LSD1 knockout using 
Cre Pitx1 mice resulted in normal pituitary morphogenesis. However, there was complete 
loss of GH and TSHβ cells and a marked decrease of LHβ and ACTH containing cells as 
well, indicating that LSD1 is necessary for the differentiation of all five hormone 
secreting cell types in the pituitary (Wang et al., 2007). 
Essential Glucocorticoids, the Receptor and the Mechanism of Action 
Essential Glucocorticoids 
Glucocorticoids (GC) are produced in the adrenal cortex and are known as the 
essential permissive hormone. They are necessary for life; however, they do not initiate 
most processes, rather they allow the process to proceed. GCs regulate in intermediary 
nutrient metabolism, the cardiovascular and central nervous system, the inflammatory 
and immune responses, and development. The hallmark role of GCs is to increase 
glucose availability for the central nervous system (CNS) by decreasing glucose 
utilization in the rest of the body (Griffen & Ojeda, 2004). Developmentally, GCs are 
necessary for the fetal development of several organs, including the lung and intestine. 
 GCs’ more well known and practical mechanism of action is the anti-
inflammatory response and gene repression. Inflammation is a natural response to 
intracellular damage or an extracellular challenger. Proinflammatory signals include 
lipopolysaccharide (LPS; found in the cell wall of bacteria), viruses, IL-1 β and tumor 
necrosis factor (TNF) (Griffen & Ojeda, 2004). GCs are used pharmacologically to 
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reduce inflammation. The review here will primarily focus on GCs role in activation of 
transcription. 
Structure of the Glucocorticoid Receptor 
GR is evolutionarily conserved from Xenopus and Teleost to rat and human. One 
GR gene has been identified with multiple promoters and multiple splice variants and 
multiple translational isoforms (Yudl & Cidlowski, 2002). Chicken GR shows 86-98% 
amino acid homology with human, pig, rat, mouse, tilapia and frog (Yudl & Cidlowski, 
2002). Phylogenetically, it clusters more closely with human and rat as opposed to frog 
and tilapia. GR is composed of three major domains: a ligand binding domain (LBD), a 
DNA binding domain (DBD), and the transactivation domain (TAD) (Beck et al., 2010). 
These three domains are highly conserved (Beck at al., 2010). The TAD is responsible 
for transcriptional activation and contains a sub-domain known as activator function 1 
(AF-1). Basal transcription cofactors bind in the TAD (Bodwell et al., 1993). The DBD 
binds to the DNA double helix and is responsible for dimerization with other nuclear 
receptors. The DBD contains two zinc fingers that intercalate into the DNA double helix. 
The LBD contains a pocket for the ligand, protein/chaperone/cofactor binding sites, and a 
second transactivation domain (AF-2). Two nuclear localization signals exist between the 
DBD and the LBD; one is ligand-dependent and one is ligand-independent (Beck et al., 
2010).  
 
Regulation of GR 
GRα is the primary isoform, and GRβ was found to be the dominant negative 
isoform as it lacks the LBD (Oakley et al., 1997). GRβ can regulate GRα by sequestering 
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coactivator complexes (Charmandari et al., 2006). GR can be post-translationally 
modified via phosphorylation, acetylation, nitrosylation, redox regulation, ubiquitination, 
and SUMOylation (Beck et al., 2010). The GR gene is negatively regulated by GCs due 
to the presence of a negative GRE. It is also regulated by AP-1, NF-kB, and CREB 
binding sites located in the promoter (Beck et al., 2010).  
Mechanism of Action of the Glucocorticoid Receptor 
GR is held inactive in the cytoplasm by a multimeric complex. Within this 
complex is heat shock protein 90 (Hsp90). Hsp90 physically interacts with GR’s ligand 
binding domain, and it stabilizes the ligand binding pocket of GR indirectly (Figure 4). 
High affinity binding of the ligand to GR requires Hsp90 (Ricketson et al, 2007). Other 
proteins in this complex include Hsp70, p23 (binds to Hsp90), Hop (an Hsp-organizing 
protein), FK506-binding protein 51 and 52, cyclophilin 40, Hsp70 interacting protein, 
and PP5. The other major function of this complex is to keep the nuclear localization 
(NLS) inactive (Beck et al., 2010). Hsp90 also promotes the stability of other steroid 
hormone receptors and some kinases (Kovacs et al., 2005). The activity of Hsp90 is 
regulated by acetylation by the deacetylase, HDAC6. Inactivation of HDAC6 leads to 
Hsp90 hyperacetylation, dissociation from an essential co-chaperone, p23, and loss of 
chaperone activity. Interestingly, in HDAC6 deficient cells, GR activity is compromised 
(Kovacs et al., 2005). Further investigation of the HDAC6 knockdown phenotype 
resulted in the discovery that GR itself is not affected; rather the interaction between 
hsp90 and GR is destabilized. The destabilization is due to a hypoacetylated state of 
hsp90 (Murphy, et al., 2005). When ligand enters the cell, Hsp90 dissociates, and the 




Figure 4: The mechanism of action of the glucocorticoid receptor (GR). CORT enters the cell and binds to 
GR. GR is held inactive in the cytoplasm by a complex of proteins, including heat-shock protein 90 
(hsp90). Upon CORT binding, the receptor undergoes a conformational change, dissociates from the 
complex and translocates to the nucleus. Once in the nucleus, CORT-bound GR homodimerizes with 
another GR receptor and the dimer binds to a classical response element. Then coactivator complexes and 
accessory factors are recruited. Last, RNA polymerase II is recruited and gene transcription ensues.   
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conformational change and the nuclear localization signal is exposed. GR is chaperoned 
to the nucleus with the help of importin α and Nup62 (Savory et al., 1998 & Echeverria et 
al., 2009). 
There are numerous conflicting reports regarding the location of GR. Classically, 
GR is held in the cytoplasm unless ligand-activated and then it is translocated to the 
nucleus. Although, a snapshot of a cell will reveal that the majority of unliganded GR is 
in the cytoplasm and liganded GR is in the nucleus, there is constitutive shuttling of the 
receptor, such that at any given time, unliganded GR will be found in the nucleus at much 
lower levels (Beck et al., 2010). Importin α and β along with the NLS signals are 
responsible for the import of GR into the nucleus, ligand bound or not; while 
CRM1/exportin1 is responsible for nuclear export. A GR nuclear retention signal was 
also found recently (Carrigan et al., 2007). Another study focused on receptor location 
and ligand selection. GR distribution between the cytoplasm and the nucleus was random 
when bound to cortisol, but it was nonrandom when bound to the synthetic agonist, 
triamcinolone acetonide (Schaaf et al., 2005). A closer look revealed that ligands that 
induced a nonrandom distribution of the receptor between the cytoplasm and the nucleus 
actually slowed migration of the receptor, whereas ligands that induced a random 
distribution did not impede the mobility of the receptor. This same study showed that 
receptor mobility and distribution are dependent upon the type of ligand, and ultimately 
the effect was a change in gene transcription. However, more sophisticated 
methodologies can reveal a snapshot of the living cell, such as using RNA fluorescence 
in situ hybridization (FISH) to label the MMTV promoter and a GFP-GR fusion protein. 
GR occupancy on the DNA was studied in individual cells. This showed that even within 
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a relatively homogenous cell population, the occupancy, duration and frequency of 
dissociation of receptor from DNA varied widely (Voss et al., 2006).  
Once glucocorticoids diffuse freely into the cell and bind to the GR, the complex 
dissociates, exposing the NLS, and GR moves along cytoskeletal tracts to enter the 
nucleus. The protein, doublecortin-like (DCL), is associated with microtubules. Using 
over expression and knockdown studies in COS-7 cells, it was found that DCL controls 
GR translocation to the nucleus (Fitzsimons et al., 2008).  
Regulation of Transcription by GR 
GR can positively regulate transcription three different ways: it can bind as a 
homodimer to a glucocorticoid response element (GRE) to activate transcription, it can 
bind directly to DNA and either displace or prevent a different transcription factor from 
binding to its cognate binding site; and it can couple with other transcription factors and 
bind to a composite element (Necela & Cidlowski, 2004) (Figure 4). GR can also 
negatively regulate transcription as seen in its anti-inflammatory role. GR can bind as a 
single receptor to a negative GRE; sequester a transcription factor away from its response 
element; bind to a negative composite element with another transcription factor; or 
prevent another transcription factor from binding to the DNA element (Beck et al., 2010).  
 GR’s natural ligand can be cortisol or CORT, depending on the predominant 
circulating glucocorticoid of the species. Upon ligand binding, GR translocates to the 
nucleus and can bind to DNA. Ligand/GR complexes are continuously disassembled off 
of the DNA response element by an active process. The LBD is essential for this 
phenomenon. However, the dissociation of GR from GREs is faster in the absence of 
ligand, and the receptor exhibits ligand-specific exchange rates. Plus, ligand dissociation 
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is not required for receptor dissociation from GREs (Meijsing et al, 2007). These studies 
have elegantly shown that the response resulting from GR binding to its response element 
is actually a culmination of many different minute mechanisms tailored at the 
ligand/receptor and receptor/response element levels. 
 GR physically interacts most notably with AP-1, NFκB/RelA, and STAT3/5; 
although this interaction usually results in transcriptional repression of the gene. The anti-
inflammatory response mediated by AP-1 and NFκB/RelA is repressed by GR. GR’s 
DBD interacts with either AP-1 or NFκB to repress gene transcription (De Bosscher et al. 
2003). The binding of GR to a transcription factor results in the sequestration of that 
factor away from the DNA response element. GR interacts with members of the Orphan 
Nuclear Receptors, such as Nurr77 in a similar manner as the GR/AP-1 interaction 
(Martens et al., 2005). A protein-DNA array was made to determine which transcription 
factors are regulated by interaction with GR (Jiang et al., 2004). The group overexpressed 
human GR in COS-7 cells, crosslinked proteins to DNA, immunoprecipitated with a 
human GR antibody, and hybridized the immunoprecipitated proteins to a DNA array. 
They validated the study using luciferase transactivation assays and supershift 
experiments. Additional transcription factors found to interact with GR include 
CTCF/E47, COUP-TF, and IRF. Pit-1 was on the array, but was not found to interact 
with GR (Jiang et al., 2004). However, it should be noted the experiments were 
performed in COS-7 cells, a green monkey kidney cell line, which does not express 
endogenous GR. 
To activate transcription, GR binds to a glucocorticoid response element (GRE). 
The classic GRE is an imperfect palindrome of six base-pair half sites with a three base-
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pair spacer in between (Strahle U et al., 1987). The consensus GRE is 5’ GGT ACA nnn 
TGT TCT. Dimerized GR binds in the major groove of the DNA via its two zinc fingers 
(Beck et al., 2010). Inspection of a large number of genes found that “glucocorticoid 
regulated genes” conspicuously lack a classic GRE, implying that the “classic” GRE is 
not the most common, but rather one of the first identified. A recent study using ChIP-
chip technology in the A549 lung carcinoma cell line identified genes regulated by GR 
occupancy (So et al., 2007). Using free source software, Weblogo, they identified a more 
relaxed glucocorticoid response element. This glucocorticoid binding region (GBR) is 
still 15 base pairs long but from that only 5 base pairs and the spacing are highly 
conserved. The conserved GBR identified is RGNACARRRWGTNCN, where R is a 
purine, N is any nucleotide, and W is an A or a T. Further, there is an enrichment of 
particular motifs occurring in close proximity, such as AP-1, HNF4, C/EBP, ETS family, 
and SP1 (So et al., 2007). Another group identified glucocorticoid response units (GRU) 
in acute lymphoblastic leukemia cell lines. The GRU closely resembles a degenerate 
GRE half site (Geng et al., 2008). In close proximity to each GRU was either a c-myb or 
ETS-1 motif, demonstrating again the possibility of gene regulation by hetero-complexes 
binding to composite response elements. Another approach to finding and analyzing GC 
regulated genes involved four treatment groups: with or with GC and with or without 
cycloheximide to identify direct GC targets and indirect targets (Chen et al., 2003). The 
RNA was extracted and hybrized to the Affymetrix oligonucleotide array. 44 genes were 
found to be directly regulated by GC. Analysis of 8 kb of flanking sequence from eight of 
the GC-regulated genes revealed a consensus sequence of ACAnnnTGTnCT. Although 
there is some degeneracy in the consensus sequence, there are definitely conserved 
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nucleotides and spacing. Variability in GREs has been an extensive area of study 
recently. The positive prediction of functional GREs will be essential in advancing this 
field, since GCs are pharmacologically important and necessary for life. 
Cofactors and their role in transcriptional regulation 
Transcription factors that frequently work in concert with GR include Sp1, 
STAT1/3/5, C/EBP, Ets1, Egr-1, AP-2, AP-1, and NF-κB (Beck et al., 2010). GRIP1, 
GR-interacting protein 1, was originally discovered as a corepressor of GR during 
tethering to AP-1 (Beck et al., 2010). The phosphorylation state of GR regulates its 
association with cofactors (Hsu et al., 1992).  
A highly studied gene that is induced by cAMP and interleukin-1 and inhibited by 
GR and glucocorticoids is surfactant protein A (SP-A) (Islam et al., 2008). Surfactant 
protein aids in the lubrication of the delicate lung tissues that allows for the transition 
from fluid filled lungs to air filled lungs that occurs at birth. SP-A expression is further 
mediated by thyroid transcription factor 1 (TTF-1) and nuclear factor B (NF-κB). GR 
interacts with TTF-1 and NF-κB at the response element. Knockdown of GR results in 
increased SP-A expression. Treatment with DEX increased recruitment of endogenous 
GR and histone deacetylase (HDAC)-1 and -2 and blocked binding of conserved helix-
loop-helix ubiquitous kinase (CHUK or IKKα). Inspection of the chromatin environment 
revealed that DEX treatment blocked acetylation and phosphorylation of histone H3 and 
mediated the dimethylation of H3 K9 at the SP-A promoter (Beck et al., 2010). GR is a 
complex and dynamic protein; it interacts with DNA alone or in conjunction with other 
transcription factors and can aid in changes to the local chromatin environment through 
histone modifications. This well studied gene demonstrates regulation at the level of the 
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promoter/response element, transcription factors and their binding partners, and the local 
chromatin environment. Regulated gene expression is typically the culmination of these 
three levels of control.  
 Accessory factors also facilitate the binding of GR to its response element. GC 
regulate the phosphoenolpyruvate carboxykinase (PEPCK) gene. Using nuclear extracts 
and the consensus GRE or a degenerate GRE; it was found that GR bound longer and 
with more frequency to the consensus GRE. Binding was further enhanced with the 
presence of COUP-TF/HNF4 and HNF3 (Stafford et al., 2001).  
 A growing class of proteins known as nuclear receptor coregulators modulates the 
transcriptional activity of steroid receptors. GCs suppress corticotropin-releasing 
hormone (CRH) in a classic negative feedback loop. Regulation of this gene by GC, GR 
and nuclear receptor regulators was studied in AtT-20 cells. Overexpression of steroid 
receptor coactivator 1a (SRC1a) increased efficacy and potency of the GC-mediated 
repression of the CRH gene (van der Laan et al., 2008). However, nuclear receptor 
corepressor (NCoR) and silencing mediator of the retinoid and thyroid hormone receptor 
(SMRT) had no effect on the GC-regulation of the gene, but did modulate the forskolin-
induced increase in CRH activity (van der Laan et al., 2008). 
 Coregulators have been described for all of the steroid and nuclear receptors. 
They can enhance or repress gene expression, depending on the cell type and signaling 
milieu. RNA pol II transcribes genes into complementary RNA. The enzyme is part of a 
large complex with ~30 additional proteins which constitute the basal transcriptional 
machinery. Coregulators were initially described as bridging complexes that connect 
basal transcriptional machinery to more specific DNA-binding transcription factors 
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(Lonard et al., 2007). An important distinction regarding coregulators is their function. 
They possess enzymatic activity, aid in transcriptional elongation, RNA splicing, and 
mRNA transport. The enzymatic activities demonstrated thus far include 
acetyltransferase, methyltransferase, phosphokinase, ubiquitin ligase, and ATPase. As 
coregulators possess different enzymatic activities, they are also regulated by different 
posttranslational modifications, such as phosphorylation, acetylation, and methylation. 
The first nuclear receptor coregulators cloned were steroid receptor coactivator 1 (SRC-
1), SMRT, and N-CoR. Almost 300 different coregulators have been described in the 
literature. To date, research has not demonstrated that coregulators exhibit NR specificity. 
Knockout studies of coregulators reveal that many result in embryonic lethality (Lonard 
et al., 2007).  
 The SRC family consists of three members: SRC-1, -2, and -3. SRC-2 is also 
known as TIF2 or GRIP1. SRC-3 is also known as AIB1, RAC3, ACTR, pCIP, and 
TRAM-1 (Lonard et al., 2010). SRC family members have been assigned the role of 
integrating hormone and growth factor signaling. SRC family knockouts do not result in 
embryonic lethality, suggesting redundancy in function at the very least, but there are 
lasting effects on reproduction, growth and energy metabolism (Lonard et al., 2010). 
Most genes are regulated at some level by a SRC family member or a coregulator. The 
GnRH-R gene is responsive to GCs and GnRH via an AP-1 site (Kotitschke et al., 2009). 
GR is required for this response, as demonstrated by siRNA, as is the interaction between 
GR and SRC-1.  
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GR and the Local Chromatin Environment 
Evidence that GR directs changes to the local chromatin environment is shown in 
the study of GR interacting with HMG1 (Agresti et al., 2005). Most nuclear proteins 
reside on a specific chromatin site for only seconds or less. There are two models 
regarding this: the “hit-and-run” model where transcription factors form complexes in a 
random fashion from freely diffusible proteins, or the stepwise model where factors 
assemble in an orderly fashion to form stable holocomplexes. High mobility group 1 
(HMG1) interacts with GR only in close proximity to chromatin and not in the 
nucleoplasm. GR and HMG1 decrease each other’s mobility and the assembled complex 
is stable. Disassembly is affected by active, ATP-consuming processes (Agresti et al., 
2005).  
 HMG1 binds linear DNA with moderate affinity and no sequence specificity 
(Calogero et al., 1999). It bends the double helix significantly by binding in the minor 
groove. But it binds sharply bent DNA with high affinity. Sharply bent DNA would be 
linker DNA that is located at the entry and exit of nucleasomes. It is recruited to DNA by 
interactions with proteins that are required for basal and regulated transcription. 
Interestingly, Hmg1-/- mice are born alive but die within 24 hrs of birth due to 
hypoglycemia. Cell lines lacking Hmg1 grow normally, but genes that are regulated by 
GR are not expressed or expressed at low levels (Calogero et al., 1999).   
 A research tool to study GR is the murine mammary tumor virus (MMTV). The 
promoter of the MMTV genome has multiple consensus GREs. GR-mediated 
transactivation of the MMTV promoter requires chromatin remodelers (Trotter & Archer, 
2004). BRG1 is a chromatin remodeler in the SWI/SNF family. This family of proteins 
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was originally discovered in yeast (SWI/SNF=mating-type switching/sucrose 
fermentation) (Winston & Carlson, 1992). Arsenic represses GR-mediated chromatin 
remodeling (Barr et al., 2009). The presence of activated GR on the MMTV promoter can 
result in a change in histone modifications.  
Glucocorticoid Regulation of Chicken GH During Embryonic Development 
Overview 
In chickens, GH mRNA in the caudal lobe of the anterior pituitary increases from 
e16 and reaches a maximum on e20 (Kansaku et al., 1994).  After embryonic 
development, GH levels do not vary in birds during different reproduction stages: pre-
laying, laying, 1-week incubation, 3-week incubation and brooding.  During these 
reproduction stages, caudal lobe GH mRNA is significantly higher than that in the 
cephalic lobe, although both lobes show no life-stage effects (Kansaku et al., 1994).   
Glucocorticoids from the adrenal gland stimulate the differentiation of 
somatotrophs in the anterior pituitary gland.  Our group has previously shown that 
somatotrophs become a significant population of chicken anterior pituitary cells between 
embryonic day 14 and embryonic day 16 (e14-e16) (Porter et al., 1995a), although a few 
appear as early as e12.  Somatotrophs in culture do not differentiate autonomously.  
Further, cell division is not necessary for induction of somatotroph differentiation (Porter 
et al., 1995b). Elucidation of this signal began with culturing pre-somatotroph 
populations of pituitary cells with serum obtained from e12 embryos and e16 embryos. 
The serum from e12 embryos did not induce cultured pituitary cells to secrete GH, but 
serum from e16 embryos did induce GH secretion. Finally, pre-absorption of e16 serum 
with an antibody against CORT abolished the serum-induced secretion of GH. Thus, the 
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blood-borne signal was determined to be CORT (Morpurgo et al., 1997).  The most 
effective dose of CORT to induce somatotroph differentiation was found to be 2.5 nM, a 
physiologically relevant concentration.  Further studies have demonstrated that CORT 
increases GH mRNA and protein and increases the number of cells that secrete GH. 
CORT seems to be the extra-pituitary signal causing GH secretion in previously non-
hormone secreting pituitary cells. However, the question remains, what is the underlying 
mechanism of the CORT induction of the chicken GH gene during embryonic 
development? 
Coincidentally with the ontogeny of pituitary somatotrophs, serum levels of 
CORT rise significantly between e12 and e16 in the embryonic chicken. In developing 
embryos, CORT increased significantly between e14 and e15 from 11.3 ng/mL to 20.4 
ng/mL as measured by RIA, and CORT remained at this concentration until e20, when a 
significant decrease was observed (Kalliecharan & Hall, 1974). Other adrenal steroids, 
such as cortisol, peaked at e15 in the chicken at 22.3 ng/mL, while cortisone peaked at 
e17 at 25.7 ng/mL. Nonadrenal steroids, such as progesterone, exhibited a steady increase 
from e9 to e20 with a peak at e20 at 31.2 ng/mL, which is different from the profile for 
glucocorticoids. An alternative study found that serum CORT levels in the embryonic 
chicken were 3.6 ng/mL on e10 and three times as much (9.0 ng/mL) on e20, determined 
by RIA (Scott et al., 1981). CORT steadily rose during the last half of incubation. Serum 
levels of CORT on e10 through e16 were statistically different from the previous day. 
However, serum levels on e16 through e20 were not statistically different from the 
previous day (Scott et al., 1981). Thus, multiple studies have indicated that adrenal 
glucocorticoid secretion increases around the time of somatotroph differentiation.   
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Treatment of cultured e11 chicken embryonic pituitary cells with the GR-specific 
antagonist, ZK98-299, did not result in the blocking of the CORT induced increase in GH 
mRNA and protein levels, suggesting that CORT is able to bind to an alternative 
receptor. The CORT induction of GH mRNA was only blocked when pretreatment with 
ZK98-299 also included spironolactone, a MR specific antagonist.  
The effects of CORT in chickens are also seen at the whole embryo level by 
treating embryos in ovo on e11, a few days before normal somatotroph differentiation 
(Bossis & Porter, 2000).  The somatotroph population increased significantly by e13 with 
a treatment dose of 0.2 g and 2 g.  However, the observed increase in the number of 
somatotrophs did not persist later in development (e16) through post-hatch day (d) 1.  
The same doses administered on e8 and e9 and then examined two days later did not 
result in an increase in the number of somatotrophs.  Clearly, there is a predetermined 
timeline of when somatotroph precursor cells are responsive to CORT, between e11 and 
e12.  GH secretion from cultured chicken embryonic pituitary cells was measured using 
an ELISA during the second half of development, under basal conditions and in response 
to CORT. Pituitary cells were responsive to CORT until e16. The cells were 
nonresponsive on e18 and e20. The age at which the cells become nonresponsive was 
mathematically determined to be e16.4 (Heuck et al., 2009). Administration of CORT too 
early in development results in embryonic death and when given later in development, 
the cells are already partially differentiated and do not respond to CORT.  
CORT is known to induce chicken somatotroph differentiation in vitro, and 
GHRH induces the cultured GH cells to release their stored GH (Dean et al., 1997).  
Sensitivity to GHRH increases in an age-dependent manner between e16 and e20. The 
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combination of CORT and GHRH significantly increased the amount of GH secreted by 
e12 anterior pituitary cells into the cell culture medium after two and six days, while 
neither agent alone had any measurable effect (Dean & Porter, 1999). As stated 
previously and reconfirmed with these results, CORT induces somatotroph differentiation 
and increases the number of somatotrophs in culture, while GHRH induces the cells to 
release their stored GH into the surrounding environment.   
 CORT increases GH mRNA, but the induction of GH gene expression is delayed 
and requires protein synthesis (Bossis & Porter, 2003).  However, the identity of the 
protein(s) required is not known.  Induction of GH gene expression may involve one or 
several signal transduction cascades.  Through the use of signaling cascade enzyme 
inhibitors, it was found that the PKA and PKC signal transduction cascades do not 
mediate the effects of CORT.  On the other hand, a RAS GTPase is involved in this 
process (Bossis & Porter, 2003). Inhibition of the protein Ras with manumycin did block 
the CORT induced increase in GH mRNA, suggesting that a Ras/MAPK mechanism may 
be involved. 
 Since co-treatment of CORT and GHRH increases GH mRNA, the GHRH 
receptor should be more thoroughly explored as the potential terminal differentiation 
factor. GHRH binds to a G-protein coupled receptor, a seven transmembrane domain 
protein, the GHRH receptor. Upon binding, the Gs is activated and the α subunit 
dissociates from the membrane bound protein and activates adenylate cyclase, causing an 
increase of cAMP, and activation of PKA. CREB is an immediate downstream target of 
PKA. First, glucocorticoids increase GHRH-R mRNA in rat pituitary cell lines and fetal 
rat pituitary glands in culture, but not so in chickens. Concomitant treatment with CORT 
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and forskolin (FSK) or IBMX, which increase cAMP accumulation and activate PKA, 
increases GH mRNA over that of CORT alone; however, treatment of FSK or IBMX 
alone did not have an effect on GH mRNA (Bossis & Porter, 2003). This suggests that 
GHRH can regulate GH mRNA, but it is not the terminal differentiation factor. Blocking 
either PKA or PKC with inhibitors did not block the CORT induced increase in GH 
mRNA. Although there is evidence that thyroid hormones and GHRH modulate the 
CORT regulation of GH; these regulatory hormones are not the differentiating factor for 
GH.  
In a cDNA microarray experiment to determine possible genes that are involved 
in somatotroph differentiation, pituitaries dissected from chickens of embryonic age e10, 
e12, e14 and e17 were assayed for genes expressed during this crucial time. Specifically, 
genes that exhibited the same expression profile or clustered with GH using self-
organizing maps (SOM) analysis were identified as potential candidates involved in GH 
gene induction (Ellestad et al, 2005). GH gene expression steadily increased between e12 
and e17, in accordance with previous findings. Genes that also increased steadily between 
these ages were identified and highlights include glucocorticoid-induced leucine zipper 
(GILZ), RAS-DVA, dexamethasone-induced ras-related protein 1 (Dexras1), stress-
induced phosphoprotein 1 (STIP1) and FK506-binding protein 51 (FKBP51).  Two other 
genes, mineralocorticoid receptor (MCCR) and JUN, an oncogene that either decreased 
steadily or decreased dramatically on e17, are also possible candidates (Ellestad et al, 
2005). Are these genes involved in somatotroph differentiation? Possibly, but definitive 




In a follow-up microarray experiment, e11 CEP cells were pretreated with 
cycloheximide for 1.5 h and then treated with CORT at the 1.5 h, 3 h, 6 h, 12 h, and 24 h 
time points. The cells were collected and the total RNA was extracted and amplified for 
hybridization to the cDNA microarray. This study identified genes that are dramatically 
up-regulated or down-regulated in the presence of cycloheximide and coincides with the 
increase of GH mRNA by treatment with CORT (unpublished data). A list of genes was 
generated, including Dexras1, RAS-DVA, and FK506BP-51.  
The effects of CORT on somatotrophs are not only seen in chickens, but also in 
mammals.  Glucocorticoids induced somatotroph differentiation in fetal rats in vitro using 
explants of fetal pituitary primordia obtained on day 14 of gestation (Hemming, 1988).    
In cultured rat pituitary cells obtained from 13.5 day-old fetal rat pups and maintained in 
culture for 8 days, cortisol stimulated the differentiation of GH-cells (Sato & Watanabe, 
1998).  Similar effects were seen in 16.5 day-old fetal pituitary cells that were maintained 
in culture for 5 days. Dexamethasone (DEX) is a synthetic glucocorticoid and is similar 
to CORT in structure and action.  Pregnant rats were given DEX in their drinking water 
for 40 hrs before sacrifice (Nogami et al., 1993).  This treatment increased GH cells in 
the anterior pituitary gland of the fetus on fetal day 18.  The observed effect was 
decreased earlier in development, as seen in the diminished effect observed on day 17 
and the nonexistent effect on day 16. Finally, spontaneous autonomous differentiation of 
pituitary cells in culture into GH-secreting cells is not observed (Nogami & Hisano, 
2008). 
Administration of DEX to the pregnant mother in her drinking water elicited an 
induction of GH-cell differentiation in the fetal rat pups.  Normally, somatotroph 
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differentiation is not observed until e18, and under these conditions, somatotrophs 
differentiated on e17. Administration of DEX and T4 augmented the previously observed 
increase in somatotroph differentiation (Nogami et al., 1995). DEX increases GH 
mRNA-containing cells obtained from e18 rat pituitary cells; however, the increase 
observed never exceeded that of intact e19 rat pituitary cells (Nogami et al., 1997). The 
same treatment on e16 did not show this, implying that somatotrophs are responsive to 
glucocorticoids at distinct time points during development.  The DEX-induced increase in 
GH-containing cells was not observed after 5 or 10 h and was only observed after a full 
24 h.  As in chickens, the addition of a protein synthesis inhibitor completely abolished 
the DEX-induced increase in GH positive cells.  
GR mRNA is first detected on e15 in the pituitary in the rat. GR co-localized in 
ACTH producing cells and not in GH producing cells. The number of cells expressing 
GR, but not ACTH increased on e18. A significant population of GH cells on e19 also 
expressed GR (Nogami & Hisano, 2008). 
 
Differences between the Chicken and Human Genomes and the Implications 
In 2004, the chicken genomic sequence was released with 6.6x coverage (Wallis 
et al., 2004). The chicken is touted as the modern descendant of dinosaurs and it was the 
first non-mammalian amniote to have its genome sequenced. Additionally, the chicken 
itself is a major agricultural food product and is at the center of a billion dollar industry. 
The chicken genome is roughly 1 billion base pairs, and it contains 20 to 23 thousand 
genes. The human genome is 3 billion base pairs coding for 30 thousand genes. The 
human genome is about three times the size of the chicken genome, and this is due to the 
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substantial expansion in interspersed repeat content, pseudogenes and segmental 
duplications. There are, however, long blocks of segmented alignments, and this 
corresponds to conserved synteny between the chicken and human genomes. Protein-
coding genes have higher synteny than non-coding RNA genes. The independent 
evolution of birds and mammals can be partially attributable to stark differences in 
multigene families. Further, there are very few pseudogenes and short interspersed 
elements (SINEs) in the chicken (Wallis et al., 2004). Comparison of the chicken and the 
human at the genome level can provide clues as to the differences between genetic 
regulation of these divergent species. 
The Embryonic Chicken as a Model for Endocrine Cell Differentiation 
The embryonic chicken is an ideal model for both endocrine studies and cell 
differentiation studies. Since the chicken develops in ovo, outside of the hen’s body, there 
is little to no interference by maternal hormones.  The mammalian placenta is a large 
reservoir for 11β-HSD2. This enzyme converts GCs into their inactive form. This is a 
protective mechanism for mammalian species in that excess GCs during gestational 
development are highly deleterious to the fetus. Since the chicken develops outside of the 
maternal body, circulating GCs are not a problem. Another benefit of the chicken model 
is accurately timed development. With mice, pregnancy is typically determined by 
evidence of a copulation plug in the female mouse. This plug is usually only found the 
following morning after placing the mating pair together the previous evening. Based on 
this, developmental age could be poorly estimated by as much as twelve hours. In 
contrast, chicken embryonic development can be accurately timed and coordinated by 
placing them in a 37 
o
C incubator. This allows for the simultaneous collection of 
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hundreds of embryos at the same age. Eggs can easily be manipulated for injection of 
treatments and dissection of tissues from the embryo. Likewise, organs and tissues can 
quickly be collected and immediately frozen or the cells can be dispersed and cultured in 
as little as two hours.  
Conclusions and Future Directions 
 
The GH gene is controlled by Pit-1 binding to consensus binding sites upstream 
of the GH gene. Pit-1 is necessary for GH expression, but it is not sufficient. GCs are 
necessary to induce GH in vitro and in vivo, but studies have shown that they do not act 
alone. There is evidence for the involvement of thyroid hormone, retinoic acid, GHRH, 
C/EBPα, and CREB. Other transcription factors involved include Sp1 and Zn-15. 
Regulation of the GH gene in the human occurs at the LCR because the human GH gene 
is in a cluster of five other closely related genes that must be expressed in different 
tissues. Other species have only one GH gene and, therefore, an LCR does not exist. The 
GH promoter has been studied extensively, aiming to identify the trans-activating factors 
necessary for regulated GH induction. The purpose of the present research was to 
investigate the role of cis-acting elements in the 5’ flanking region in the GC regulation 
of the GH gene during chicken embryonic development. 
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Chapter 2: Characterization of the Chicken Growth Hormone Gene 
 
Introduction 
Growth hormone (GH) is produced in the anterior pituitary gland by cells known 
as somatotrophs and regulates long bone growth, muscle accretion, lipolysis, and nutrient 
utilization (Griffen & Ojeda, 2004). GH contributes to the lean phenotype of the modern 
broiler chicken that is becoming a staple in the American diet. Exogenous GH has either 
no effect or negative effects on post-hatch growth of chickens. Broilers have a higher 
baseline level of GH, which may account for the lack of exogenous GH. Thus, distinct 
differences regarding the regulation of growth exist in the domesticated chicken due to 
selective breeding. However, the mechanism of action initiating GH secretion is still 
unknown.  
Current research in our laboratory centers on the onset of GH secretion, 
differentiation of somatotrophs, and the extra-pituitary signals that regulate this 
phenomenon using the chicken as a model. The chicken is a unique model for studies of 
pituitary development because the head is relatively large compared to mammalian 
species, thus providing more cells; there is little maternal endocrine interaction as in 
mammals; and the egg allows for easy manipulation of the embryo for a multitude of 
experiments. Furthermore, it is more feasible to obtain the large number of embryonic 
pituitary cells necessary for cell culture experiments than from common mammalian 
models, because embryonic development can be precisely timed and controlled by 
artificially incubating the eggs. 
The anterior pituitary contains five distinct cell types, corticotrophs, 
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gonadotrophs, thyrotrophs, somatotrophs and lactotrophs, which differentiate sequentially 
in that order and are spatially restricted. Gonadotrophs secrete luteinizing hormone and 
follicle-stimulating hormone, thyrotrophs secrete thyroid-stimulating hormone (TSH), 
somatotrophs secrete growth hormone, and lactotrophs secrete prolactin. Corticotrophs 
differentiate first around embryonic day (e) 7 and begin to secrete adrenocorticotrophic 
hormone (ACTH) that then maturizes the adrenal gland (Woods et al., 1971). 
Differentiation of somatotrophs naturally occurs between embryonic day (e) 14 and 16 
(Porter et al., 1995a).  Plasma corticosterone (CORT), originating from the adrenal gland, 
and ACTH dramatically increase between e11 and e17 (Jenkins et al., 2007), mimicking 
the pattern of somatotroph abundance and preceding the increase in plasma GH levels. 
GH secretion can be induced earlier (e11 and e12) both in ovo and in vitro through 
administration of CORT (Dean & Porter, 1999). CORT is the extra-pituitary signal that 
induces final somatotroph differentiation in embryonic chickens (Morpurgo et al., 1997). 
Further evidence using pharmacological inhibitors shows that CORT-induced 
somatotroph differentiation involves both the type I (mineralocorticoid, MR) 
glucocorticoid receptor and the type II (glucocorticoid, GR) corticosteroid receptors and 
requires the chaperone protein Hsp90 (Bossis et al., 2004).  
GR protein is detected in pituitary extracts as early as e8, while MR wasn’t 
detectable until e12 (Bossis et al., 2004). GR was expressed in about 95% of all pituitary 
cells, while MR was expressed in about 40% of pituitary cells. Co-localization studies 
revealed that most GH containing cells expressed both MR and GR (Bossis et al., 2004). 
GR and MR mRNA levels peak at e14, concomitant with the normal differentiation of 
GH cells (Heuck et al., 2009). 
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 Induction of GH mRNA by CORT can be blocked in vitro by pre-treating 
anterior pituitary cells with cycloheximide (CHX), a protein synthesis inhibitor (Bossis & 
Porter, 2003). This suggests that either one or more proteins must be synthesized first for 
CORT induction of GH cell differentiation or that on-going protein synthesis is 
necessary. Plus, examination of 10 kilo-bases (kb) upstream of the GH gene and 5 kb 
downstream reveals no full-length consensus glucocorticoid responsive element (GRE). 
Therefore, it seems that CORT induction of GH is an indirect effect. This leads to the 
formation of two hypotheses: 1) the product of an unknown glucocorticoid-responsive 
gene induces the GH gene; 2) ligand bound GR and an unknown protein bind to an 
unknown composite element in the 5’ flanking region of the GH gene and induce the GH 
gene together (Figure 5). 
The promoters of the GH gene of many other species have been characterized to 
date, including mouse, human, rat, dog, cow, grass carp and chicken. The studies have 
focused on the necessary transcription factors involved in the induction of GH. Pit-1 is 
the most studied, tissue-specific, required transcription factor for the GH gene. Pit-1 is a 
required transcription factor for somatotrophs, lactotrophs, and thyrotrophs (Zhu et al., 
2007). It is necessary, but not sufficient, for full expression of these three cell types 
(Nelson et al., 1988). Pit-1 has a conserved binding site located less than 200 bp upstream 
of the transcription start site of all of the GH genes studied. Most of the promoters also 
contain a functional, distal Pit-1 binding site. Within the same proximal region of the Pit-
1 binding site of the rat GH gene, lie putative binding sites for thyroid hormone receptor 





Figure 5: Two hypotheses: A) the product of an unknown glucocorticoid-responsive gene induces the GH 
gene; B) ligand bound GR and an unknown protein bind to an unknown composite element in the 5’ 




transcription factors, plus other unknown transcription factors, can direct expression of 
GH, prolactin and TSH (Lira et al., 1988). 
Pit-1 is necessary for pituitary-restricted expression of GH; however, other 
molecules are definitely involved in the regulation of GH gene expression. Thyroid 
hormone (T3) and retinoic acid (RA) are known regulators of GH (Dean et al., 1997). 
Thyroid hormone response elements (TRE) were identified and found to negatively 
regulate the chicken GH gene promoter, antagonistic to Pit-1 (Ip et al., 2004).  The 
hypothalamic factor, GHRH, signals through its receptor and activates cAMP and the 
PKA pathway. The downstream target of this pathway is cAMP response element 
binding protein (CREB). CREB and Pit-1 physically interact and synergize to activate the 
rat GH gene (Xu et al., 1998). A potential candidate critical for the Pit-1-dependent 
expression of GH is a cysteine/histidine zinc finger, Zn-15 (Lipkin et al., 1993). Zn-15 
was found to synergize with Pit-1 and be necessary for full expression of the human GH 
gene in a heterologous cell type.  
Many of the studies to date have attempted to characterize the GH gene in a 
heterologous system, e.g. human GH gene in mouse and chicken GH gene in a rat cell 
line. The present study will characterize regulation of the GH gene in primary chicken 
embryonic pituitary cells. A transcription factor search using MatInspector was 
conducted on the proximal promoter of the GH genes of human, rat, mouse, and dog. 
Nine identical sites were found: a TATA box, MEF3, Pit-1, WTI, Oct-1, CEBP, IRF2, 
PRE, and STAF (Lantinga-van Leeuwen et al., 2002). There is some conservation across 
GH promoters and involvement of potential transcription factors, but the differentiating 
factor of the GH gene induction remains to be elucidated in all species. 
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There are multiple levels of regulation of the GH gene. The necessity for ongoing 
protein synthesis during CORT induction of the GH gene suggests involvement of other 
proteins. CORT induction of the chicken GH gene can be blocked by inclusion of 
manumycin, a Ras GTPase inhibitor (Bossis & Porter, 2003). However, pharmacological 
inhibitors to PKA, PKC, and MAPK did not block CORT induction of the chicken GH 
gene.   
An area of intense research involves the regulation of genes at the chromatin and 
histone level. The human GH gene is actually in a cluster of five related GH genes, where 
one is pituitary specific, GH-N, and the rest are placental specific. The cluster of genes 
are located on chromosome 17 and are regulated by a locus control region (LCR) located 
15 kb upstream of the gene cluster. Recent evidence has implicated histone lysine 
demethylase (LSD1) as a necessary player in the regulation of GH gene expression 
(Wang et al., 2007). An LSD1 knockout mouse results in early embryonic lethality, but a 
pituitary-specific LSD1 knockout resulted in the loss of all Pit-1 lineage cells, while 
maintaining a normal overall morphology of the pituitary gland. Additionally, a histone 
deacetylase (HDAC) is necessary for CORT induction of the chicken GH gene. Pre-
treatment with the HDAC inhibitors, trichostatin A or HC toxin, blocked the CORT 
response of the GH gene (unpublished data). 
In our lab, two fragments of the chicken GH gene were separately cloned into a 
luciferase reporter plasmid: -488 to +1 and -488 to +1004. Each of these constructs, as 
well as empty vector, was transfected into e11 chicken embryonic pituitary cells. The 
cells were treated with CORT and assayed for luciferase activity. Neither of the 
constructs were CORT responsive (Liu, dissertation; 2003).  
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In another study, the rat somatotroph cell line, GH4C1, was transfected with a 
luciferase reporter construct containing 1775 base pairs, spanning -1727 to +48, of the 5’-
flanking region of the chicken GH gene (Ip et al., 2004). The cells were treated with 
dexamethasone, a synthetic glucocorticoid, and luciferase activity was measured. 
Dexamethasone produced a two-fold increase in promoter activity over empty vector. 
Deletion of the -1727 bp insert to -1467 bp ablated the dexamethasone induction of 
promoter activity (Ip et al. 2004). From this, it is possible that a glucocorticoid responsive 
the region exists in the -1727 to -1467 bp region.   
Therefore, the objectives of this study were 1) to confirm that the -1727/+48 
reporter construct responds to glucocorticoids in chicken embryonic pituitary (CEP) cells; 
2) to determine if the response is specific to glucocorticoids; 3) to define the 
glucocorticoid responsive region through deletion/mutation analysis of the luciferase 
constructs; 4) to determine if activation of the -1727/+48 luciferase construct requires 
ongoing protein synthesis; 5) to identify the transcription start site of the chicken GH 
gene in e11 chicken pituitary cells; 6) to determine whether the glucocorticoid responsive 
region binds nuclear proteins using an electrophoretic mobility shift assay (EMSA); and 
7) to test for binding of specific proteins to this region using EMSA and chromatin 
immunoprecipitation (ChIP). Through characterization of the 5’ flanking region of the 
chicken GH gene and by defining the cis-acting elements of the chicken GH gene, it is 
possible to identify trans-acting candidate proteins involved in glucocorticoid induction 
of the GH gene. Uncovering the glucocorticoid-inducible element in the GH gene will 
greatly aid in understanding the mechanisms regulating somatotroph differentiation and 




Reagents and Materials 
Cell culture media and additives and transfection reagents (OptiMEM and 
Lipofectamine 2000) were purchased from Invitrogen (Carlsbad, CA). Hormones and 
other chemicals were obtained from Sigma Chemical Company (St. Louis, MO) unless 
otherwise noted.  
Pituitary dissection, dispersion, cell culture and transfection 
 
 Ross x Ross fertilized eggs were set in a 60% humidified, 37.5 
o
C incubator such 
that the first day was denoted as embryonic day (e) 0. Pituitaries were pooled from e11 
dissected embryos and dispersed with trypsin as previously described (Porter et al., 
1995a). Cells were counted using the trypan blue exclusion method, and the viability rate 
was above 95% in all experiments. Dispersed cells were plated at a density of 1x10
6 
cells/well in poly-L-lysine coated 24-well plates and were allowed to attach for one h. 
Plasmids to be transfected were diluted in sterile filtered OptiMEM (Invitrogen, 
Carlsbad, CA) to a concentration of 1 µg per well for all pGL3-Basic vector constructs 
and 10 ng per well for renilla luciferase. Diluted plasmids were combined with 
Lipofectamine according to manufacturer’s instructions. Plated cells were transfected 
with the OptiMEM/Lipofectamine/Plasmid mixture for 4 hours. The medium was 
replaced with DMEM/F12 supplemented with 0.1% BSA, 100
 
U/ml penicillin and 100 
µg/ml streptomycin, and 5 µg/ml human insulin, and cultured for an additional 20 hours. 
CORT (100nM final concentration in well) was added to appropriate wells for an 
additional 20 hours and then the cells were lysed with Passive Lysis Buffer (Promega, 
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Madison, WI) according to manufacturer’s instructions in the Dual luciferase Reporter 
Assay Kit (Promega, Madison, WI).     
Generation of DeletionLluciferase Reporter Constructs 
 
To make nondirectionally cloned deletion constructs, the original -1727 plasmid 
was used as the template in PCR amplification of the other deletion constructs. Pfx DNA 
polymerase, a recombinant DNA polymerase with 3’5’ exonuclease activity was used 
to generate all of the deletion constructs (Invitrogen, Carlsbad, CA). The primers used are 
listed in Table 1. The PCR product of each of the inserts and the Basic vector was 
incubated for 4 h at 37 
o
C and then overnight at 4
o
C with the restriction enzyme HindIII 
or KpnI (Invitrogen, Carlsbad, CA) and its appropriate buffer. The next day, shrimp 
alkaline phophatase (SAP) (Invitrogen, Carlsbad, CA) was added to the Basic vector and 
incubated at 37
o
C for 1 h, followed by phosphatase inactivation at 65 
o
C for 1 h. All 
inserts and the digested, phosphatase-treated Basic vector were then gel purified, vacuum 
dried, and resuspended in 20 µL nuclease free water. Inserts and vectors were quantified 
by both gel electrophoresis using the molecular weight ladder, DNA Ladder I (Gene 
Choice), and absorbance reading at 260 nm. Appropriate concentrations of vector and 
insert were placed in tubes in a ratio of 1:1 and 1:3 vector to insert, heated to 65 
o
C, then 
allowed to slowly cool to 37 
o
C when buffer and T4 DNA ligase were added. The 
reaction was incubated at 16 
o
C for 8 h and then at 4
o
C overnight. DH5α Max Efficiency 
Competent cells were transformed according to manufacturer’s instructions with the 
newly ligated plasmids and then ampicillin-selected colonies were counted the next day.  
Selected colonies were grown overnight in 2 mL of Terrific Broth with ampicillin (100 
µg/mL) for plasmid purification and qualification. Colony PCR was used to confirm the  
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correct size and orientation of the insert. Plasmids containing the correct size and 
orientation of the desired insert were sequenced fully by the dye terminator method in 
both directions to confirm the sequence and Nucleobond Maxi Plasmid Purification 
columns (Clontech, Mountain View, CA) were used to purify a large quantity of the 
plasmid for transfection.     
Generation of Mutant Luciferase Reporter Constructs 
 Mutant constructs were generated using the QuikChange II Site-Directed 
Mutagenesis Kit (Stratagene, La Jolla, CA) according to manufacturer’s protocol. Briefly, 
the -1045/+48 plasmid was used as the template in the PCR reaction with the following 
primers: ETS1_muta_fwd cagatgttgctggctattgggtgaaattctacctgatagctgcaggacccact, 
ETS1_muta_rev agtgggtcctgcagctatcaggtagaatttcacccaatagccagcaacatctg; 
GREF_muta_fwd ggtgaccggatacctgatagctgcaggaaaaaaggggccctctcctctggggactgaca, 
GREF_muta_rev tgtcagtccccagaggagagggccccttttttcctgcagctatcaggtatccggtcacc. After 
PCR, the reaction was incubated with DpnI enzyme for 30 m in 37 
o
C to digest the 
original template. XL1-Blue Supercompetent cells were immediately transformed with 1 
µL of the digested PCR reaction. The transformed bacteria were spread on 
TB/Agar/Ampicillin plates containing 80 ug/mL X-gal and 20 mM IPTG. Clones 
containing the correct mutations were verified by dideoxy dye terminator sequencing, and 
the selected clones were sequenced in both directions with 4x coverage. Sequencing 
reactions were performed by the University
 
of Maryland's Center for Biosystems 
Research DNA Sequencing
 
Facility with AmpliTaq-FS DNA polymerase and Big Dye 
terminators
 
with dITP in an Applied Biosystems DNA Sequencer (Model 3100;
 
Foster 
City, CA, USA). 
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Analysis of Luciferase mRNA in transfected cells 
To determine the effect of protein synthesis inhibition on the activity of the 5’ 
flanking region of the chicken GH gene, e11 chicken embryonic pituitary cells were 
dispersed, plated at a density of 4x10
6
 cells per well, and transfected with pGL3_ -
1727/+48 GH construct (1.45 µg), renilla luciferase (0.01 µg), and a Golgi-targeted green 
fluorescent protein (GFP) expression plasmid (1.45 µg) (Pecot & Malhotra, 2004). The 
transfection reagents were replaced with fresh medium at 6 h post-transfection. At 22.5 h 
post-transfection, the cells were treated with cycloheximide (10 µg/mL final 
concentration in well) for 90 min and then CORT [1 nM] was added at 24 h post-
transfection. The cells were incubated for another 21 h and then collected using trypsin 
digestion and washed one time each with SMEM, DMEM, and PBS. The cells were 
sorted based on GFP fluorescence as previously described (Ellestad et al., 2009) and 
collected into Buffer RLT from the RNeasy Mini Kit (QIAGEN, Valencia, CA). The 
RNA was extracted immediately following the manufacturer’s protocol with the optional 
on-column DNA digestion and quantified using the Ribogreen Quantitation Kit 
(Invitrogen, Carlsbad, CA). 20 ng of total RNA was reverse transcribed into cDNA using 
Super Script III according to manufacturer’s instructions (Invitrogen, Carlsbad, CA). A 
volume of 2 µL of the diluted cDNA sample was used for analysis. Three-step qRT-PCR 
was used to quantify cDNA levels using a Bio-Rad iCycler. The final concentration of 
the reaction mixture was 0.1% Triton X-100, 10mM Tris–HCl, 50mM KCl, 1.9mM 
MgCl2, 2U Taq, 10mM each dNTP, 1µM each primer, 20nM fluorescein, and SYBR® 
green II (Bio Rad, Hercules, CA). The cycling parameters were 40 cycles of 95 
o
C for 15 
s, 60 
o
C for 30 s, and 72 
o
C for 30 s. All primers used to quantify cDNA are listed in 
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Table 2. Primers were designed to span an intron where appropriate to ensure 
amplification of cDNA and not genomic DNA. Relative cDNA levels for each sample 
were calculated using the relative Ct method (level = 2
(Ct of the no RT−control−Ct of the sample)
), as 
previously described (Ellestad et al., 2005). 
5’ Rapid Amplification of cDNA Ends (RACE) 
Anterior pituitaries were dissected and pooled from e11 chicken embryos. The 
pituitaries were dispersed as described previously and plated at a cell density of 1x10
6 
cells per well in a 24-well plate. The cells were allowed to recover overnight and were 
treated with CORT [100 nM] for 24 hours before retrypsinization and snap freezing of 
the cell pellet. RNA was extracted from the frozen cell pellet using the RNeasy Mini Kit 
(Qiagen) and the samples were quantified using ribogreen dye. One µL of RNA was used 
in the 5’RACE System for Rapid Amplification of cDNA Ends kit (Invitrogen, Carlsbad, 
CA), according to the manufacturer’s protocol. The GH gene specific primer 1 (GSP1) 
used was 5’-CACGGGGGTGAGCCAGGACT-3’ and the GH gene specific primer 2 
(GSP2) used was 5’- TCCCCGTGGGAGCTGGGATG-3’. The primers were tested on 
cDNA first to verify correct specificity. The single PCR product generated was 
sequenced in both directions using the dideoxy dye terminator method with the primers: 
GHGSP2 and the Universal Abridged Adaptor Primer (UAAP) included in the kit. 
Preparation of Nuclear Extracts 
Twenty million cells per treatment were cultured for 6 h in the presence or 
absence of CORT (1x10
-9
 M). Cells were scraped on ice, collected into 15 mL centrifuge 




Table 2: Primers used for quantitative Real Time PCR 




Actin Beta fwd CAGGATGCAGAAGGAGATCACA
Actin Beta rev TAGAGCCTCCAATCCAGACAGAGTA
ETS-1 fwd GCCGGCTACACAGGCAGTGG
ETS-1 rev ACCGCCTGGCCACCTCATCT
Renilla Luc fwd AGGTGGTAAACCTGACGTTGTACA
Renilla Luc rev ATCCTGGGTCCGATTCAATAAAC
Firefly Luc fwd TTGGAATCCATCTTGCTCCAA
Firefly Luc rev TCCGTGCTCCAAAACAACAA
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according to the method as described previously with modifications (Dignam et al., 
1993). The cells were washed once in 1.5 mL of hypotonic buffer (10 mM HEPES pH 
7.9, 10 mM KCl ,1.5 mM MgCl2, 0.2 mM PMSF, and 0.5 mM DTT), collected and 
resuspended in 1 mL of hypotonic buffer, and then incubated on ice for 10 min. The cells 
were transferred to a 1 mL size Dounce homogenizer fitted with a tight pestle. The cells 
were homogenized with 40 up-and-down strokes. An aliquot of cells were checked under 
the microscope for loss of cell membrane and retention of nuclei with trypan blue. The 
cells were transferred to a microcentrifuge tube and centrifuged at 3300 g for 15 min. The 
cytoplasmic fraction was removed and saved. In the cold room (4 
o
C), the nuclear pellet 
was rapidly resuspended in 120 µL of low salt buffer (20 mM HEPES pH 7.9, 25% 
glycerol, 0.02 M KCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.02 PMSF and 0.05 mM DTT). 
The same volume of high salt buffer (20 mM HEPES pH 7.9, 25% glycerol, 1.4 M KCl, 
1.5 mM MgCl2, 0.2 mM EDTA, 0.02 PMSF and 0.05 mM DTT) was added drop-wise 
while mixing the tube in between drops. The sample was placed on a rotator (end to end) 
at 4 
o
C. The sample was checked to ensure that the liquid sample was moving inside of 
the tube and incubated for 30 min. The sample was then centrifuged for 30 min at 
maximum speed. The buffer was replaced in the nuclear extract using Microcon 
Centrifugal Filter Devices (YM-10) (Millipore) following manufacturer’s instructions. 
The sample was quantified using Coomassie Plus: The Better Bradford Reagent (Pierce) 
with absorbance at 560 nm.  
Electrophorectic Mobility Gel Shift Assays (EMSA) 
EMSA probes were designed for the proximal (-1042/-956) and distal GCRR (-
1496/-1465), proximal Pit-1 binding site (-133/-103), and exon 3 (+207/+237of the 
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chicken GH gene. 5’ infrared labeled oligonucleotides (0.1 pmol/µL) were annealed at 
100 
o
C for 5 min and then allowed to cool slowly (Integrated DNA Technologies, 
Coralville IA). One µL of probe and 2.5 µg of nuclear extract were added to the binding 
reaction. The binding reaction [buffer (10 mM Tris, 50 mM NaCl, 1 mM DTT, pH 7.5), 
50 ng sheared salmon sperm DNA, 5 mM MgCl2, 2.5 mM DTT and 0.25% Tween 20, 
0.2% NP-40] was incubated for 30 min on ice in the dark. For super-shift experiments, 
nuclear protein and the appropriate antibody were incubated in the binding reaction 
mixture overnight at 4
o
C. The next morning, the infrared labeled probe was added for 30 
min before loading the entire reaction onto the gel. The gel was pre-run for 30 min at 70 
V in 0.5 X TBE. Orange loading dye (LI-COR, #927-10100) was added to each sample 
and loaded into the gel. The gels were electrophoresed for 3 h at 70 V and imaged on a 
Li-COR Odyssey Infrared Imaging System using intensity level 8 (Li-COR Biosciences, 
Lincoln, NE).    
Western Blot for ETS-1 
 A western blot for ETS-1 was performed in order to determine specificity of the 
ETS-1 antibody (catalog # sc-112; Santa Cruz Biotechnology, Santa Cruz, CA). Total 
protein was obtained from embryonic chicken liver and adult rat liver, as previously 
described (Proszkowiecz-Weglarz & Porter, 2010).  Nuclear protein was obtained from 
e20 chicken embryonic pituitary cells and GH4C1 cells, a rat somatotroph cell line. Equal 
protein amounts (12 µg) were subjected to SDS-PAGE under reducing conditions on 
7.5% gel.  The transfer and blotting procedure was performed as described previously 
(Proszkowiecz-Weglarz & Porter, 2010). The ETS-1 antibody was used at 1:1000. The 
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secondary antibody was a horseradish peroxidase-conjugated donkey anti-goat IgG 
(1:5000; GE Healthcare Life Sciences, Piscataway, NJ).  
Cell Culture and Chromatin Preparation 
 E11 chicken embryonic pituitary cells were dissected and dispersed as previously 
described. Twenty-five million cells per treatment were plated with 6 mL of DMEM/F12 
supplemented with 0.1% BSA, 100
 
U/ml penicillin and 100 µg/ml streptomycin, and 5 
µg/ml human insulin in 4 100 mm x 20 mm Corning
®
 cell culture petri dishes and 
allowed to recover overnight. The next morning, the cells were treated with either vehicle 
or CORT [1 nM] for six h. At that time, 200 µL of 37% formaldehyde was added drop-
wise while swirling to each dish. The dishes were placed on a rotator for 10 m at RT. 
Then 625 µL of 1 M glycine was added for 5 m to quench the formaldehyde. The plates 
were placed on ice and the cells were scraped into 50 mL conical tubes. The dishes were 
washed twice with 2 mL of ice-cold PBS containing 1 mM PMSF. The cells were 
collected at 3000 g and the pellet was washed once with PBS containing 1 mM PMSF. 
The cells were resuspended in swelling buffer [25 mM Hepes pH 7.8, 1.5 mM MgCl2, 10 
mM KCl, 0.1% NP-40, 1 mM DTT, 0.5 mM PMSF, and 1x Halt Protease Inhibitor 
Cocktail (Thermoscientific, Rockford, IL)] and incubated on ice for 10 m. The cell 
suspension was homogenized with a Dounce homogenizer with 15 up and down strokes 
using a loose fitting pestle. The cells were transferred to 15 mL conical tubes and 
centrifuged at 1800 g for 5 m. The cells were resuspended in 2 mL of Mononuclease 
(MNase) Buffer (0.32 M sucrose, 50 mM Tris-HCl pH 7.4, 4 mM MgCl2, 1 mM CaCl2, 
0.1 mM PMSF, 1% SDS) and homogenized with a Polytron PT 1200 C (Kinematica, 
Bohemia, NY) for 30 s on ice. Fifteen µL of the cell solution was removed at this time 
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and stored as the “non-sheared control.” Ten µL of BSA and 7.5 µL of mononuclease 
(MNase) enzyme (New England Bio Labs, Ipswich, MA) were added to each sample and 
incubated at 37 
o
C for 15 m. 100 µL of 0.5 M EDTA was added to stop the reaction. The 
samples were then stored overnight at -80 
o
C. The next day, the samples were sonicated 
in an ice-ethanol bath for 5 cycles (20 s continuous pulse, output at 60%, power at “6”) 
using a Branson Sonifier 250. The samples were centrifuged at 14,000 rpm for 10 m, and 
the supernatant was collected into a new tube and quantified using Quant-it Picogreen 
DNA Quantification Kit (Invitrogen, Carlsbad, CA). The quantified chromatin was 




For each immunoprecipitation (IP), 10 µg of sheared chromatin was precleared 2x 
for a total of 24 h at 4 
o
C with rotation with prewashed protein A magnetic beads (New 
England Bio Labs, Ipswich, MA), 0.25 mg/mL normal rabbit serum. The next day, the 
cleared chromatin was transferred to a new tube, and 5 µL of the appropriate antibody 
was added and incubated overnight at 4 
o
C with rotation. The next morning, the 
chromatin was incubated with prewashed protein A magnetic beads (New England 
Biolabs, Ipswich, MA) for 5 h at 4 
o
C with rotation. The beads were washed 2x each with 
low salt wash buffer (50 mM Hepes pH 7.9, 140 mM NaCl, 1 mM EDTA, 1% Triton X-
100, 0.1% Na-deoxycholate, 0.1% SDS, 0.5 mM PMSF, 1x Protease Inhibitor Cocktail), 
high salt wash buffer (50 mM Hepes pH 7.9, 500 mM NaCl, 1 mM EDTA, 1% Triton X-
100, 0.1% Na-deoxycholate, 0.1% SDS, 0.5 mM PMSF, 1x Protease Inhibitor Cocktail), 
LiCl wash buffer (20 mM Tris pH 8.0, 1 mM EDTA, 250 mM LiCl, 0.5% NP-40, 0.5% 
Na-deoxycholate, 0.5 mM PMSF, 1x Protease Inhibitor Cocktail), and TE buffer wash 
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(10 mM Tris pH 8.0, 1 mM EDTA). The immunoprecipitated chromatin was eluted from 
the beads with elution buffer (50 mM Tris pH 8.0, 1 mM EDTA, 1% SDS, 50 mM 
NaHCO3) at 65 
o
C with rotation for 30 m. The supernatant was transferred to new tubes 
containing 15 µL of 5 M NaCl and 25 ng RNase A and incubated at 37 
o
C for 30 m. 
Next, 250 ng of Proteinase K (Sigma Aldrich, St. Louis, MO) was added, and the samples 
were incubated at 65 
o
C with rotation overnight. The next day, the samples were purified 
using the Wizard SV PCR clean up kit according to manufacturer’s instructions 
(Promega, Madison, WI) with the following modification: the final product was eluted 
twice with 40 µL of water. 
Real Time PCR of Immunoprecipitated Chromatin  
 Three-step qRT-PCR was used to quantify immunoprecipitated DNA levels using 
a Bio-Rad iCycler. The final concentration of the reaction mixture was 0.1% Triton X-
100, 10mM Tris–HCl, 50mM KCl, 1.9mM MgCl2, 2U Taq, 10mM each dNTP, 80 nM 
each primer, 20nM fluorescein, and SYBRgreen II. 4 uL of the immunoprecipitated DNA 
was used in each 30 µL reaction. The primers used are listed in Table 3. The cycling 
parameters were 40 cycles of 95 
o
C for 15 s, 60 
o
C for 30 s, and 72 
o
C for 30 s. Before 
immunoprecipitation, 2% of the sheared chromatin sample was removed and saved as the 
“input”. The starting input fraction was 2%; therefore a dilution factor (DF) of 50 or 
5.644 cycles (i.e., log2 of 50) was subtracted from the Ct value of the diluted input. The 
input Ct values were adjusted to 100% efficiency by subtracting 5.64 from each. All Ct 
values were adjusted to % of input using the equation 100*2
(adjusted input Ct-sample Ct)
 (Haring 








Name Start site Sequence
GCRR fwd -1065 TTTAAACACGACCTGGAGCAGAAAAA
GCRR rev -859 ATTTCCAAGAGCAGCATCATCAC
distal control fwd -1436 ATGATCCTTTGGGTTGCA




Each experiment was replicated 3 to 5 times, as indicated. Using the SAS 
statistical program (SAS Inc; Cary, NC), statistically significant differences among 
treatments or groups were determined employing a mixed model ANOVA, where 
replicate experiment was a random effect in the model. An a priori test of least 
significant differences (LSD) with a Tukey method of adjustment to control the 
experiment-wise error rate was used to determine significant differences between groups. 
Differences were considered significant at p≤0.05. In figures, an asterisk or different 
letters denote significance at p≤0.05.  
Firefly luciferase was normalized to renilla luciferase, and then relative luciferase 
data were transformed into log scale to correct for heterogeneity of variances between 
groups and non-normality. The least squared means (LSMeans) were back-transformed 
and then normalized to the -1727/+48 plasmid, or a different plasmid as indicated, for 
graphical representation. 
Real Time qRT-PCR values for firefly luciferase or GH were normalized to 
renilla luciferase or β-actin, respectively. The delta delta Ct value was then log 
transformed to correct for variance heterogeneity and non-normality and for significance 
testing. The log transformed data was back-transformed for graphical representation.  
Results 
Luciferase Activity of the -1727/+48 Insert in Response to CORT 
In order to confirm CORT responsiveness of the -1727/+48 GH luciferase 
construct, we used GH4C1 cells, a rat somatotroph cell line. The day of the transfection, 
the cells were washed twice to remove any traces of glucocorticoids from the fetal bovine 
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serum. The cells were transfected with 1 µg of either the -1727/+48, -1467/+48, or pGL3-
Basic plasmid and 20 ng of the renilla luciferase plasmid per well for 4 h. The next day, 
CORT was added to appropriate wells and then the cells were lysed for determination of 
luciferase activity. The addition of the -1727/+48 GH fragment resulted in an eight-fold 
increase in basal luciferase activity over the empty vector (Figure 6A). Alternatively, the 
addition of the -1467/+48 GH fragment resulted in only a four-fold increase in basal 
luciferase activity over the empty vector. CORT treatment did not affect activity of the 
empty vector, pGL3-Basic. CORT treatment of the -1727/+48 plasmid resulted in a 
significant five-fold increase in luciferase activity, while CORT treatment resulted in a 
slight increase of luciferase activity from the -1467/+48 plasmid, although this response 
was not significant (n=3; p<0.05) (Figure 6A). Values denoted by different letters are 
significantly different at p<0.05. Thus, the -1727/+48 GH construct was CORT 
responsive in GH4C1 cells, and this response was lost with deletion down to -1467/+48.   
The -1727/+48 Luciferase Construct is CORT-inducible in Embryonic Chicken Pituitary 
Cells. 
The initial experiment was replicated using chicken embryonic primary pituitary 
cells. E11 pituitary cells were dispersed and transfected immediately for 4 h with the 
plasmids: basic, -1727/+48, or -1467/+48, and renilla luciferase. 24 h after the conclusion 
of transfection, the cells were treated with vehicle or 100 nM CORT.  21 h later, the cells 
were lysed and assayed for luciferase activity. Insertion of the -1727/+48 GH fragment 
into the pGL3-Basic vector resulted in a two-fold increase in basal luciferase activity 




 Figure 6: Mean Relative Luciferase Activity of the GH Constructs in Response to CORT. 1 x 107 cells 
were transfected with either the Basic Luciferase empty vector, -1727/+48 GH Luciferase or   -1467/+48 
GH Luciferase and allowed to recover overnight. The cells were treated with CORT (100 nM) the next day 
and assayed for Luciferase activity 24 h later. A) GH4C1  rat somatotroph cell line, B) e11 chicken 





in a 50% increase in basal luciferase activity. CORT treatment did not affect luciferase 
activity of the empty vector. CORT (100 nM) treatment significantly increased luciferase 
activity of the -1727/+48 plasmid an average of six-fold over vehicle; however, the -
1467/+48 was not CORT responsive (n=3; p<0.05) (Figure 6B). Values denoted by 
different letters are significantly different at p<0.05. Therefore, the -1727/+48 GH 
construct was CORT responsive in chicken embryonic pituitary cells, and this response 
was lost with deletion down to -1467/+48.  
 
The -1727/+48 Luciferase Construct is Responsive to Corticosterone and Progesterone. 
E11 pituitary cells were dispersed, transfected with either the -1727/+48 plasmid 
or basic vector and allowed to recover overnight. 24 h after the conclusion of transfection 
the cells were treated with vehicle or various steroids: CORT, aldosterone, testosterone, 
estradiol and progesterone (100 nM) to define the specificity of the response to CORT. 
The cells were lysed and assayed for luciferase activity 21 h after addition of the 
treatments. Addition of CORT resulted in a significant 10-fold induction of the -
1727/+48 luciferase plasmid as compared to vehicle (n=3; p<0.05) (Fig. 7), whereas 
treatment with aldosterone, testosterone, or estradiol did not produce a significant 
increase. Progesterone treatment resulted in a partial increase in luciferase activity that 
was not significantly different from basal or CORT. Values denoted by different letters 
are significantly different at p<0.05. Therefore, the -1727/+48 GH construct was 





Figure 7: Mean Relative Luciferase Activity in Response to Steroid Hormones. 1 x 10
7
 cells were 
transfected with either the Basic Luciferase empty vector or the -1727/+48 GH Luciferase and allowed to 
recover overnight. The cells were treated with different steroid hormones the next day and assayed for 




The -1727/+48 Luciferase Construct Is an Appropriate Model for CORT Induction of the 
Endogenous GH Gene. 
The chicken GH gene is induced by glucocorticoids, and this effect can be 
blocked with the addition of cycloheximide (CHX), a protein synthesis inhibitor. This 
implicates an unknown protein in the CORT induction of GH. Therefore, it is important 
that the luciferase activity driven by the -1727/+48 insert of the 5’ flanking region of the 
chicken GH gene is induced by glucocorticoids and that the induced activity is blocked 
by cycloheximide.  In other words, does this artificial system recapitulate the activity of 
the endogenous chicken GH gene?  
To this end, mRNA levels of firefly luciferase and renilla luciferase in response to 
CORT and CHX alone and in combination were quantified using qRT-PCR. E11 chicken 
embryonic pituitary cells were dispersed and transfected in suspension with a GFP 
expression vector, renilla luciferase and either the -1727/+48 firefly luciferase plasmid or 
Basic firefly luciferase plasmid for 2 h. The transfected cells were plated at a density of 4 
x 10
6
 cells per well in a 12-well plate and incubated for an additional 4 h before the 
transfection reagents were replaced with fresh medium.  At 22.5 h post-transfection, the 
cells were treated with cycloheximide (10 µg/mL final concentration in well) for 90 mins 
and then CORT was added at 24 h post-transfection. The cells were incubated for another 
21 h and then collected using trypsin digestion and washed twice. Positively transfected 
cells were sorted, based on GFP expression. The sorted cells were collected, and RNA 
was immediately extracted including an on-column DNA digestion step. Total RNA was 
reverse-transcribed into cDNA and used in qRT- PCR (n=4; p<0.05). Firefly luciferase 
mRNA was normalized to renilla luciferase mRNA as a control for transfection 
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efficiency (Fig 8A). GH mRNA, normalized to β-actin, was also quantified in the same 
samples (Fig 8B). Values denoted by different letters are significantly different at p<0.05. 
Firefly luciferase mRNA transcribed off the -1727/+48 construct increased about 80 fold 
in response to CORT, and this response to CORT was blocked by pre-treatment with 
CHX. CORT treatment induced firefly luciferase mRNA from the -1727/+48 insert four-
fold compared to CORT-treated Basic plasmid. CORT induced GH mRNA regardless of 
the transfected plasmid (-1727/+48 vs. Basic), and the CORT induction of GH mRNA 
was blocked by pretreatment with CHX. Thus, on-going protein synthesis was required 
for CORT induction of the -1727/+48 GH construct and the endogenous GH gene.  
The Transcription Start Site of the Chicken GH Gene is the Same as the -1727/+48 
Luciferase Construct. 
 In order to define the transcriptional start site of the endogenous GH gene, CORT-
treated chicken e11 pituitary cells were cultured overnight and then treated with CORT 
[100 nM] or vehicle for 6 h. The cells were collected using trypsin, snap frozen and RNA 
was extracted. The transcriptional start site of the GH gene was determined using the 5’ 
RACE system for rapid amplification of cDNA ends kit (Invitrogen, Carlsbad, CA). A 
single product was observed from the nested PCR reaction (Fig.9A). The gel band was 
excised, purified and sequenced. The resulting chromatogram and sequence are shown 
(Fig. 9B). The start codon, known 5’ UTR, and the new 5’ end of the chicken GH gene 
are highlighted. The sequence of the 5’ RACE product was aligned with the chicken 
genomic sequence from the Ensembl website (www.ensembl.org), which is based on the 





 Figure 8: Mean Relative mRNA levels of Firefly Luciferase and GH in Response to CORT. 4 x 10
7
 cells 
were transfected with Basic empty vector or the -1727/+48 GH Luciferase plasmid and the Renilla 
Luciferase plasmid and a GFP expression plasmid (3 µg total). Cells were treated with cylcoheximide for 
90 m and then CORT for 20 h and then sorted based on GFP expression. RNA was extracted immediately, 
reverse transcribed into cDNA and quantified with qRT-PCR. A) Firefly mRNA normalized to Renilla 
mRNA, B) GH mRNA normalized to β-actin mRNA. Values denoted by different letters are significantly 





Figure 9: 5’ Rapid Amplification of cDNA Ends (5’ RACE) of the Chicken GH Gene.A) PCR results of 
tailed cDNA reaction, Left: “no reverse transcriptase” reaction, Center: 100 bp ladder, Right: “reverse 
transcriptase” reaction. B) chromatogram and sequencing results of 5’ RACE product. C) alignment of 





chicken GH gene plasmid (Fig. 9C). Sequence analysis of the 5’ RACE product indicated 
that the transcription start site resides at -56 bp of the GH gene.  
Deletion Constructs of the -1727/+48 Luciferase Construct Reveal Two Potential 
Glucocorticoid Responsive Regions.  
The -1727/+48 luciferase plasmid was used as the template to generate 
progressively shorter deletion constructs of the 5’ flanking region of the chicken GH 
gene, in order to identify the glucocorticoid responsive region. Nine additional deletion 
constructs were cloned into the luciferase plasmid and tested for CORT responsiveness 
(Fig. 10 & 11A) by transfection into e11 pituitary cells as previously described. The -
1467/+48 firefly luciferase plasmid remained unresponsive to CORT. The shorter -
1430/+48, -1398/+48, and -1201/+48 constructs were CORT responsive, while the -
954/+48, -807/+48, and -382/+48 constructs were not CORT responsive (p<0.05; n=3). 
Values denoted by different letters are significantly different at p<0.05. One additional 
deletion construct was made, -1045/+48, tested and was found to be CORT-responsive 
(p<0.05; n=3) (Fig. 11B). Values denoted by different letters were significantly different 
at p<0.05. Therefore, a glucocorticoid inhibitory region (GC-IR) was identified between -
1477 and -1430 and a proximal GCRR was identified between -1045 and -954 of the 
chicken GH gene. Further experiments are warranted for characterize the GC-IR and its 
role in glucocorticoid induction of the GH gene during chicken embryonic development.  
Identification of Putative Transcription Factor Binding Sites in the Proximal GCRR  
 CORT responsiveness of the chicken GH gene was lost when the 5’ flanking 
region was deleted down to -954. Potential transcription factors involved in regulating  
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Figure 10: Scaled schematic of the deletion luciferase constructs.  
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 Figure 11: Mean Relative Luciferase Activity of Deletion Constructs in Response to CORT. A) Nine 
deletion constructs. B) One additional deletion construct (-1045/+48) to narrow down the region to less 




GH gene expression can be identified by examining the sequence between -1045 and -
954 of the chicken GH gene. Two transcription factor search engines were used to 
generate this list: MatInspector (Quant et al., 1995) and JASPAR (Sandelin, et al., 2004) 
(Fig. 12). MatInspector is based on a position weight matrix, a conservation profile and a 
core region to identify putative transcription factor binding sites. The matrix is the entire 
transcription factor binding sequence (up to 15 bp). A matrix similarity score is 
calculated by matching the query sequence to the matrix or pattern. The highest score 
possible is 1 when the test sequence corresponds to the most conserved nucleotide at each 
position of the matrix. The core region or core similarity is the set of 4 to 5 nucleotides 
that is the most conserved in the transcription factor binding site. Thus, two scores can be 
calculated: matrix similarity and core similarity (Cartharius et al., 2005). Using the 
vertebrate database in the MatInspector program and a cutoff of 0.9 identity (10% error) 
to the matrix, putative transcription factor binding sites were identified, including 
CTCF/E47, RP58, NFY (CAAT-box binding protein), ETS-1, GREF (glucocorticoid 
responsive and related elements), RUSH (SMARCA3), and TALE (Fig. 12A). The 
putative GR binding site as identified by MatInspector was classified as a “glucocorticoid 
responsive and related elements”. The algorithm identified the following sequence, 
aggGAACagtgggtcctgc, where the upper case letters match the conserved core element 
and the underlined letters match the overall matrix. The core similarity score was 1.0 and 
the matrix similarity score was 0.94. The putative ETS-1 site as identified by 
MatInspector was: gggtgaCCGGatacctgatag, where the upper case letters match the 
conserved core element and the underlined letters match the overall matrix. The core 
similarity score was 1.0 and the matrix similarity score was 0.93.  
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 Figure 12: Potential Transcription Factors of the -1045 to -954 Region of the Chicken GH Gene. Two 
different internet based search engines with their associated databases were employed. A) MatInspector 






JASPAR-CORE is based on the same weight matrix scoring, however, the library is 
smaller. Using the vertebrate database in the JASPAR-CORE program and a cutoff of 0.9 
identity (10% error), different putative transcription factor binding sites were identified 
(Fig. 12B). The factors include GATA2, GATA2/3, NFIC, ETS1, ZEB2, ZNF354C, 
MZF1, FOXC1, and HOXA5 (Fig. 12B). Each program generated a list of potential 
transcription factor binding sites and these two lists were different. The differences are 
attributed to the different databases; the JASPAR database is much smaller than the 
MatInspector database. Notably, ETS-1 was the only putative transcription factor binding 
site identified by both programs. A brief description of each putative transcription factor 
binding site, the orientation of that site, and the consensus sequence are listed in the table 
in Fig. 12C.   
The GRE Half Site Located in Intron 1 Did Not Increase the CORT Response of the -
1727/+48 firefly luciferase Plasmid.  
 A half site of a canonical GRE is located in intron 1 (+302 to +320) of the chicken 
GH gene. Another report indicates that a half site GRE located in intron 1 of the human 
GH gene was functional (Kolb et al., 1998). To address whether or not the purported half 
site in the chicken GH gene is functional as well, -1727 to +1004 inclusive of intron 1, 
was cloned into the firefly luciferase plasmid and tested (Fig. 13A & 14A). Previously, 
two fragments of the GH gene were separately cloned into a luciferase reporter: -488/+1 
and -488/+1004. Neither of these constructs was found to be responsive to CORT (Liu, 
dissertation; 2003). By cloning the fragment containing -1727/+1004 into a Luciferase 
reporter, it may be possible to answer the question of functionality of the intron 1 half site 




Figure 13: Scaled Schematic of Additional Constructs Produced and Tested. The black bar is the -1045 to -
954 region. The white bar is the -1045 to -954 region inserted in the reverse orientation. A) Additional 
constructs made of the 5’ flanking region of the GH gene. B) Additional constructs made using 1272 bp of 







Figure 14: Mean Relative Luciferase Activity of Additional Constructs in Response to CORT. A) 
Comparison of the -1727/+48 GH promoter to the -1727/+1004 GH promoter that includes intron 1. Values 
denoted by different letters are significantly different (n=3; p<0.05). B) GCRR orientation in response to 






-1727/+1004 plasmids, and then treated with vehicle or CORT the next day. The cells 
were lysed 24 h later for determination of luciferase activity. CORT treatment of the -
1727/+48 plasmid resulted in a significant 12-fold increase in luciferase activity. CORT 
treatment of the -1727/+1004 plasmid resulted in a significant 6-fold increase in 
luciferase activity. The CORT induced luciferase activity was significantly different 
between the two -1727 plasmids (n=4; p<0.05). Values denoted by different letters are 
significantly different at p<0.05. Thus, inclusion of intron 1 and the GRE half site did not 
significantly increase responsiveness to CORT. 
Analysis of Additional Firefly Luciferase Constructs Shows that the GCRR Requires 
Additional Sequence Elements for CORT Responsiveness. 
The -1045/+48 GH construct is the shortest plasmid that retained CORT 
responsiveness, and the responsiveness was lost with deletion down to -954 of the 5’ 
flanking region of the GH gene. To further characterize the -1045 to -954 GCRR, ten 
additional constructs were made in order to test whether the proximal GCRR is position-, 
orientation-, or context-independent (Fig. 13A). The GCRR was placed in the reverse 
orientation in the -1727/+48 and -1045 plasmids (white bar). The GCRR was placed, in 
both the forward (black bar) and reverse directions (white bar), and moved closer to the 
transcription start site by deleting the intervening sequence between -953 and -650 and 
between -953 and -382. Similarly, in the -1727/+48 plasmid, intervening sequence 
between -1045 and -650 was deleted, and the GCRR was re-inserted in both orientations. 
Finally, the segment from -1727 to -954 was placed in front of the -382/+48 region in 
both orientations.  
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 The GCRR exhibited greater CORT responsiveness when placed in the reverse 
orientation (n=4; p<0.05) (Fig. 14B). Values denoted by different letters are significantly 
different at p<0.05. The addition of the reverse GCRR to the -1727/+48 and -954/+48 
constructs resulted in an average 35-fold increase in luciferase activity, but only a 13-fold 
increase in luciferase activity when placed in front of the -650/+48 construct. The GCRR 
in the forward orientation linked to the -650/+48 exhibited a two-fold response to CORT, 
but this was not significant. The luciferase activity of the -1727/+48, with 953 to 650 
deleted and the GCRR intact, still responded to CORT about 8-fold, but this was not 
significant and the overall activity of the construct was significantly reduced compared to 
the -1727/+48 construct. However, when the GCRR, in either orientation, was linked to -
382/+48, CORT induction of luciferase activity was lost (Fig. 15A). This suggests that 
intervening sequences between -650 and -382, including the distal Pit-1 site (-541/-528), 
are required for the CORT induction of luciferase activity. Thus, other transcription 
factor binding sites between -953 and -650 are necessary for CORT responsiveness. 
Taken together, these results indicate that responsiveness to CORT through the GCRR 
requires cis-acting elements between -650 and -382 and additional elements between -
953 and -650. 
  
The GCRR Cannot Confer CORT-responsiveness to the Thyroid Stimulating Hormone β 
Promoter. 
The -1272/+1 5’ flanking region of the thyroid stimulating hormone β (TSHβ) 
subunit was cloned into the firefly luciferase plasmid. The TSHβ gene also requires Pit-1 
for expression, but it has not been shown to be induced by CORT to date. Three 






Figure 15: Mean Relative Luciferase Activity of the TSHβ Constructs in Response to CORT. A) Constructs 
using the GH promoter and the region from -1727 to -954. Values denoted by different letters are 
significantly different (p<0.05), n=3. B) Constructs using the TSHβ promoter and only the GCRR. *, 





383 was placed upstream of the TSHβ promoter, thus including the distal Pit-1 of the GH 
gene, the GCRR and all intervening sequence. Additionally, the GCRR (-1045 to -953) 
alone was placed upstream of the TSHβ promoter in both the forward and reverse 
orientation. The TSHβ promoter exhibited significantly increased luciferase activity 
compared to Basic vector (n=3; †, p<0.05) (Fig. 15B). Addition of the GCRR in either 
orientation did not affect CORT-stimulated or unstimulated luciferase activity.  Similarly, 
addition of the -1045 to -383 segment also did not affect CORT-stimulated or 
unstimulated luciferase activity (n=3; p<0.05). Thus, the GCRR of the GH gene could not 
confer CORT-responsiveness to the TSHβ gene. 
Electrophoretic Mobility Shift Assays Show that Nuclear Proteins Bind to the -1045 to -
954 GCRR. 
Nuclear proteins incubated with the -1045 to -954 proximal GCRR probe 
produced a noticeable shift of the probe, as indicated by the arrow (Fig 16A). Nuclear 
proteins incubated with the exon 3 probe or the distal GCRR probe (-1566 to -1467) did 
not produce an observable shift. Because the -1467/+48 firefly luciferase plasmid was not 
CORT responsive and the -1566 to -1467 did not bind nuclear proteins in the gel shift 
assay, additional experiments to further characterize this apparent GC-inhibitive region 
were conducted (Appendix A). However, we were unable to define the basis for the non-
responsiveness of the -1467/+48 construct. Therefore, we focused our attention on the 
proximal GCRR, which bound nuclear proteins and responded to CORT.The amount of 
the GCRR probe used in the gel shift assays was serially diluted 1:4 to show that binding 




Figure 16: Electrophoretic Mobility Shift Assay (EMSA) with Nuclear Protein Extracts (N.E.) from e11 
Pituitary Cells. A) Nuclear extract (2.5 µg) binding to the proximal GCRR probe and not the distal GCRR 
probe nor the exon 3 probe. The arrow denotes the shifted band. B) Titration of the GCRR probe. Equal 
amounts of protein were incubated with decreasing amounts of probe. The arrow denotes the shifted band. 
C) Titration of nuclear extracted proteins. Equal amounts of probe were incubated with decreasing amounts 




of nuclear protein incubated with the probe was serially diluted 1:1, as indicated by the 
arrow (Fig. 16C). In both cases, serial dilutions reduced intensity of the shifted band. In 
conclusion, the proximal GCRR probe binds nuclear proteins. 
Nuclear Extract Binding to the GCRR Probe Is Increased by CORT Treatment, and 
Competitors Show that the Observed Shift is Specific. 
 The GCRR probe was incubated with CORT- or vehicle-treated nuclear extract 
proteins (n=4) (Fig. 17A). Two shifts, one high molecular weight and one low molecular 
weight, were observed upon incubation of nuclear extracts with the GCRR probe. CORT 
treatment significantly increased binding of nuclear proteins, both high and low 
molecular weight, to the GCRR probe. The high molecular weight band was not seen in 
all experiments, so we focused our attention on the lower molecular weight band. The 
intensity of the lower molecular weight band, as indicated by the arrow, was quantified 
and normalized to the free probe lane. Quantification of the mean integrated intensity of 
the shifted band as compared to the free probe lane showed that CORT treatment 
significantly increased binding of proteins to the GCRR probe (p<0.05) (Fig. 17B).   
To determine if the observed shift with the proximal GCRR probe was specific, 
three unlabeled double-stranded DNA competitors were made: one corresponding to the 
immediate upstream region (-1201 to -1046) of the GH gene, one corresponding to the 5’ 
half of the probe, and one corresponding to the 3’ half of the probe (Fig. 17C). Nuclear 
extracts were pre-incubated with either the 5’ competitor, 3’ competitor or the upstream 
competitor in 100-fold molar excess for 30 m prior to addition of the proximal GCRR 
probe, as indicated by the arrow (Fig. 17D). The nuclear extracted proteins produced an 




Figure 17: Nuclear Protein Binding is CORT Regulated.  A) Nuclear extracts from vehicle and CORT 
treated cells (n=4). The arrow denotes the shifted bands that were used for intensity quantification. B) 
Mean integrated intensity of the shifted bands. *, denotes significant difference at p<0.05. C) Schematic of 
the 5’, 3’ and upstream competitors.  D) Binding of nuclear protein to the GCRR probe and competition 




to the probe, while addition of the upstream competitor did not abolish protein binding to 
the probe (n=4). Thus, nuclear protein binding to the GCRR probe is CORT-regulated, 
and the binding can be competed off with addition of either a 5’ competitor or a 3’ 
competitor. Because the 5’ and 3’competitors reduced binding to the probe and did not 
provide any additional insight into the region bound by proteins, another competitor was 
made. An unlabeled centered competitor that corresponds to the center 34 bp of the 
GCRR probe that spans the putative ETS-1 and GREF binding sites as identified by the 
MatInspector program was made  and tested with the nuclear extracts (Fig. 18A). Nuclear 
extracts were pre-incubated with either the upstream-competitor or the centered-
competitor in 100-fold molar excess for 30 min prior to addition of the proximal GCRR 
probe. Addition of the centered competitor abolished protein binding to the GCRR probe. 
Addition of the upstream competitor did not affect protein binding to the probe, as 
indicated by the arrow (n=4) (Fig. 18B). Taken together, regulated protein binding may 
occur in the central 34 bp of the GCRR probe, which contains putative ETS-1 and GREF 
binding sites. 
A Mutated Probe Results in Decreased Protein Binding. 
 The proximal GCRR probe binds nuclear proteins in a CORT-regulated manner, 
and this binding can be competed off through the use of a competitor DNA probe used in 
excess that corresponds to the central 34 bp and spans the putative ETS-1 and GREF 
sites. The unlabeled competitor probes were in excess and pre-incubated with the nuclear 
proteins. This could potentially create an artificial environment conducive to selective 
binding. To confirm specificity of protein binding to the GCRR, a mutated probe was 




Figure 18: EMSA with a Centered Competitor and a Mutant Probe. A) Schematic of the upstream 
competitor, the GCRR probe, and the centered competitor. “E” corresponds to the putative ETS-1 binding 
site. “G” corresponds to the putative GREF binding site. B) Specificity of nuclear extract binding to the 
GCRR probe through the use of unlabeled competitors in excess (20x). The arrow denotes the shifted band 
(n=4). C) Design of the mutated probe. D) Binding of nuclear extracts to the wild type probe versus the 
mutated probe (1, 1.2 ug; 2, 2.4 ug; 4, 4.8 ug) (n=4). E) Mean integrated intensity of the shifted bands. *, 






into the full length GCRR probe sequence, such that the flanking region was conserved, 
but the central 34 bp, although the same in nucleotide content, was different in sequence 
(Fig. 18C). The wild type or mutant probe was incubated with increasing amounts (1.2, 
2.4, 4.8 µg) of nuclear protein extracts from basal or CORT-treated e11 pituitary cells 
(Fig. 18D). The shifted band intensity increased with increasing amounts of protein. A 
shifted band of the same molecular weight was also observed with the mutant probe; 
however, intensity was significantly reduced. The shifted bands from both the wild type 
and mutant probe from 3 replicate experiments were quantified in the same manner as 
previously stated. A 3-way ANOVA (probe, treatment, protein amount) was conducted 
on the mutant vs. wild type probe data. The main effect of probe was significant; 
however, there was no main effect of treatment or protein amount, and therefore, these 
terms were eliminated from the model. The intensity of the shifted band from the mutant 
probe was significantly decreased compared to the wild type shifted band (Fig. 18E). 
These results indicate that the central 34 bp of the GCRR are important for nuclear 
protein binding. 
Transcription of ETS-1 Is Not Induced by CORT Treatment, and Super-shift Experiments 
with Antibodies to ETS-1 and GR Are Inconclusive. 
GR mRNA is expressed in e11 chicken pituitaries (Heuck et al., 2009), and it is 
not responsive to CORT treatment (unpublished data). GR protein is expressed and the 
antibody has been validated (Proszkoweicz-Weglarz et al., 2010). A western blot for 
ETS-1 was conducted to test the ETS-1 antibody (Santa Cruz Biotechnology, Santa Cruz, 
CA) using adult rat liver, adult chicken liver and nuclear extracted proteins from the 
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GH4C1 rat pituitary cell line and e20 primary chicken pituitary cells (Fig. 19A). A single 
band of the correct size (45 kDa) was observed in the chicken liver and nuclear extracted 
protein lanes (lanes 2, 3, 4). CORT induces GH mRNA after 6 h of treatment, but it does 
not affect ETS-1 mRNA (Fig. 19B). Addition of the GR, ETS-1 or rabbit IgG antibody at 
10% of the reaction volume (2 µL) in EMSA produced results that could not be 
interpreted (Fig. 19C; n=6). Addition of any antibody resulted in an upward shift of most 
of the probe, and there was no observable shifted band in the probe + protein only lanes 
(lanes 6 & 8). Unusual smearing was also observed throughout the gel. Therefore, less 
antibody was used, in order to avoid these non-specific effects. Addition of the rabbit 
IgG, GH, GR, ELK4 (an ETS-1 family member) or ETS-1 antibodies at 1% of the 
reaction volume did not affect nuclear protein binding to the probe (Fig. 19D). Addition 
of nuclear protein resulted in an observable shift of the GCRR probe (lanes 6 & 13), and 
addition of different antibodies did not affect the shifted probe (lanes 2-5 & 14-18) (n=3). 
 
Mutation of the ETS-1 and GREF Potential Binding Sites in the GH Luciferase Construct 
Results in Ablation of the CORT-Responsiveness. 
  Because there was significantly reduced binding with the mutant probe compared 
to the wild type probe in the EMSA assays, the -1045/+48 firefly luciferase plasmid was 
mutated. The ETS-1 or the GREF site was mutated using site-directed mutagenesis (Fig. 
20A). E11 pituitary cells were dispersed and transfected with either the Basic, -1045/+48, 
ETS-1 mutant or GREF mutant plasmids (Fig. 20B). The cells were treated with CORT 
the next day and assayed for luciferase activity 24 h after that. CORT significantly 
induced a five-fold increase in the luciferase activity of the -1045/+48 plasmid, while 
both the ETS-1 mutant and the GREF mutant were not CORT responsive. This study  
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 Figure 19: ETS-1 mRNA in Response to CORT and Super shift Experiments. A) Western blot for chicken 
ETS-1. Nuclear Extract=N.E. B) Mean Relative mRNA expression of ETS-1 and GH in response to 6 h 
CORT (10 nM) (n=3; p<0.05) C)Super-shift experiment using antibodies (ab) at a final concentration of 





Figure 20: Mean Relative Luciferase Activity of Mutant Constructs in Response to CORT. 1 x 107 cells 
were transfected with either the Basic Luciferase empty vector, the -1045/+48 GH Luciferase, the ETS-1 
mutant or the GREF mutant and allowed to recover overnight. The cells were treated with CORT the next 
day and assayed for Luciferase activity 24 h later. Values denoted by different letters are significantly 
different (p<0.05), n=3. B) Sequence of the wild type -1045 to -954 region and the ETS-1 and GREF 





demonstrates that the putative sites for ETS-1 and GR are indeed necessary for 
glucocorticoid regulation of the GH gene during chicken embryonic development. 
 
  ETS-1 and GR Are Associated with the GCRR and not the Distal Control Region. 
 Chromatin immunoprecipitation was performed on e11 chicken embryonic 
pituitary cells that were untreated or treated with CORT [1 nM] for 1.5 h and 6 h. 
Chromatin was immunoprecipitated with normal rabbit serum and antibodies towards GR 
(Proszkowiecz-Weglarz & Porter, 2010) and human ETS-1. Real time qRT-PCR was 
performed on the immunoprecipitated chromatin using primers corresponding to the 
proximal GCRR (-1065 to -869) and the distal GCRR (-1436 to -1299) (Fig 21). The real 
time PCR products of the proximal GCRR and the distal GCRR after 40 cycles from one 
replicate were electrophoresed on an agarose gel to check the product size (Fig 21A & B, 
respectively). Cycle threshold values from real time PCR of the input sample and the 
immunoprecipitated samples were used in a three-way ANOVA. There was a significant 
effect of region (proximal vs. distal), immunoprecipitation (IP), and treatment. The three-
way interaction was also significant (n=3; p<0.05). ETS-1 was associated with the 
proximal GCRR under both 0 h and 1.5 h CORT treatment. ETS-1 association with the 
GCRR was significantly decreased at 6 h. Association of GR with the proximal GCRR 
was increased after 1.5 h, and then decreased after 6 h. Neither GR nor ETS-1 was 
associated with the distal control region under any condition. Taken together, these 
results demonstrate that GR and ETS-1 are associated with their putative response 




 Figure 21: ETS-1 and GR are recruited to the GCRR based on chromatin immunoprecipitation of the 
proximal and distal GCRR. A) Real time PCR products after 40 cylces of the proximal GCRR primer set as 
visualized in an agarose gel from one replicate. B) Real time PCR products after 40 cycles of the distal 
GCRR primer set as visualized in an agarose gel from one replicate. C) Real Time PCR results represented 
as percent input as calculated from the cycle threshold values. Values with different letters indicate a 






 The overall objective of this study was to identify cis- and trans-acting elements 
and factors underlying glucocorticoid regulation of the GH gene during chicken 
embryonic development.  A luciferase reporter containing -1727/+48 of the 5’ flanking 
region of the chicken GH gene was used to analyze the CORT response of the GH gene. 
In our studies, it was determined that the -1727/+48 GH construct is an appropriate model 
for glucocorticoid regulation of the endogenous GH gene, because the response was 
specific to CORT, it required on-going protein synthesis, and the transcription start site 
was the same as the endogenous gene. It was also shown that the basal activity of the 
basic construct compared to the -1727/+48 GH construct was significantly increased. 
This suggests that the GH gene is under tonic repression until another unknown protein is 
activated or released. Additional studies are warranted to explore the repression of the 
GH gene under basal conditions. 
 The -1727/+48 GH construct responded to CORT treatment and possibly 
progesterone. Glucocorticoids can induce GH mRNA and protein in chickens (Porter, 
2007) and rats (Nogami, 2008). This is the second study to show that the promoter of the 
chicken GH gene was responsive to glucocorticoids. The -1727/+48 GH construct 
exhibited a 2-fold increase in response to dexamethasone when transfected into a rat 
pituitary cell line (Ip et al., 2004). Previously, only 500 bp of the 5’ flanking region of the 
chicken GH gene was cloned, but it was not tested for CORT-responsiveness (Tanaka et 
al., 1992). It is interesting to note, but not surprising, that the 5’ flanking region was 
partially responsive to progesterone. The glucocorticoid and the progesterone steroid 
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hormone receptors recognize an imperfect half site of TGTYCY, where Y is a pyrimidine 
(C or T) (Truss et al., 1991). The canine GH promoter, as analyzed in mammary tissue, is 
responsive to progestins, contains a conserved PRE, and nuclear proteins bind to a probe 
corresponding to the aforementioned PRE in gel shift assays. A super-shift with a 
progesterone receptor antibody was not performed in that study (Lantinga-van Leeuwen 
et al., 2002). Other studies have shown that aldosterone can induce GH mRNA (Bossis et 
al., 2004), but the promoter seems to be aldosterone insensitive. In another study, GH 
secretion could be induced with progesterone, corticosterone, dexamethasone, and to 
some extent, testosterone and estradiol (Morpurgo et al., 1997). Different results were 
observed based on the end point tested, i.e. mRNA, secretion of protein, activity of the 
promoter. Nonetheless, the GH gene responds to CORT at the mRNA, protein and now 
the promoter level.   
The CORT response of the -1727/+48 GH construct requires ongoing protein 
synthesis. CORT induction of GH mRNA also required ongoing protein synthesis (Bossis 
& Porter, 2003). This suggests that the underlying mechanism of CORT induction of the 
GH gene during chicken embryonic development is conserved at the promoter level. It 
also suggests that the -1727/+48 GH construct recapitulates the native system and may be 
an appropriate model for use in studies of glucocorticoid regulation of the GH gene 
during chicken embryonic development. The requirement for ongoing protein synthesis 
possibly implicates the involvement of an unknown intermediary protein in 
glucocorticoid induction of the GH gene. Glucocorticoid induction of the GH gene during 
rat embryonic development also requires on-going protein synthesis (Nogami et al., 
1997). It is possible that the unknown inducible protein is conserved between rats and 
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chickens. Identification of cis-acting elements in the upstream regulatory region of the 
chicken GH gene could aid in the identification of trans-acting proteins necessary for GH 
gene induction.  
 The transcription start site of the chicken GH gene was found to be 56 bp 
upstream from the translational start codon. The first study characterizing the chicken GH 
gene also found the transcription start site to be located 56 bp upstream from the start 
codon (Tanaka et al., 1992). Our current findings indicate that the same transcription start 
site is used during embryonic development and in response to CORT. The chicken GH 
gene, as annotated on the Ensembl website and as based on the sequence of the chicken 
genome, places the transcription start site 42 bp upstream from the start codon (Wallis et 
al., 2004). The transcription start site for the mouse GH gene was found to be 62 bp 
upstream from the start codon (Das et al., 1996). There is some variability, but it seems 
that the transcription start site is somewhat conserved between chicken, mouse, rat and 
human. If the transcription start site is conserved, then it is possible that the underlying 
mechanism of glucocorticoid induction of the GH gene during embryonic development is 
also conserved. The 5’ RACE results did not find an alternative transcription start site 
further upstream or in the first intron of the chicken GH gene. The transcription start site 
of the -1727/+48 GH construct was determined by alignment with the chicken genome. 
The conservation of the transcription start site between the endogenous gene and the -
1727/+48 GH construct also provides further evidence that the -1727/+48 GH construct is 




 Through deletion analysis of the -1727/+48 GH construct, two glucocorticoid 
responsive regions (GCRR) were identified: a proximal and a distal. The distal GC-IR 
was found to be located between -1477 and -1430, and the proximal GCRR was found to 
be located between -1045 and -954. The previous study characterizing the chicken GH 
gene concluded that a glucocorticoid response element was located between -1727 and -
1467 (Ip et al., 2004). The present study further defined this region and concluded more 
appropriately that there is a repressor region located at -1477 to -1430 and not a 
responsive region. However, future studies are necessary to determine the underlying 
mechanism of the regulation of the distal GC-IR and whether or not it is biologically 
relevant.  
 There is a putative half site GRE located at +302/+320 with the sequence of 
TGTTCT in intron 1 of the chicken GH gene The -1727/+1004 GH construct was CORT 
responsive, however, the observed response was significantly less than with the -
1727/+48 GH luciferase construct. Addition of intron 1 to the GH luciferase construct did 
not result in an increased synergistic response to CORT treatment. Research on the 
human GH gene has identified a GRE half site in the first intron that binds the GR 
complex in an exonuclease III protection/foot printing assay (Slater et al., 1985). Cloning 
of the intron 1 fragment containing the half site GRE in front of a glucocorticoid 
responsive gene devoid of its GRE, metallothionein-IIA, resulted in a three-fold increase 
in activity in response to dexamethasone treatment. The metallothionein-IIA gene devoid 
of its GRE was non-responsive to dexamethasone treatment. The intact metallothionein-
IIA containing its GRE responded six-fold to dexamethasone treatment (Slater et al., 
1985). Another study implicated a 123 bp region contained in the first intron of the 
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human GH gene that was sufficient to direct GH expression from a promoterless 
luciferase reporter (Kolb et al., 1998). It was not tested for glucocorticoid responsiveness. 
The putative half site GRE in intron 1 of the chicken GH gene did not result in 
synergistic activation of the chicken GH gene in the context of a luciferase reporter; 
however, it is still unknown whether or not this putative half site GRE binds GR in a 
regulated manner. Nonetheless, we conclude that the putative half site GRE in intron 1 of 
the chicken GH gene is not necessary for CORT induction of the GH gene during chicken 
embryonic development. 
 Additional constructs were made to determine if the CORT response of the -
1045/+48 construct was independent of GCRR orientation and context. The CORT 
response of the reverse orientation of the GCRR was significantly increased compared to 
the forward orientation of the GCRR. Therefore, responsiveness of the GCRR was not 
orientation dependent and glucocorticoid regulation of the GH gene during chicken 
embryonic development is not dependent on the orientation of the GCRR. However, the 
GCRR was context dependent. The mammalian GH gene contains two functional Pit-1 
sites: a distal and a proximal site (Lira et al., 1988 & Jin et al., 1999). The chicken GH 
gene contains a distal Pit-1 site at -541/-528 and a proximal site at -113/-104 (Ip et al., 
2004). This possibly suggests that the CORT response requires both Pit-1 elements or 
another unknown transcription factor that binds between -650 and -382. A transcription 
factor search using MatInspector was conducted on the -954 to -382 fragment, with a 
95% confidence level. From -650 to -382, besides Pit-1, there are putative binding sites 
for CREB, STAT5, EVI1, ZNF35, MZF1 and the ETS1 family members, SPI1 and PU1. 
There are conserved putative binding sites for EVI1 and MZF1 in the dog, mouse, rat and 
 101 
 
human GH genes (Lantinga-van Leeuwen et al., 2002). CREB and STAT5 are known to 
be involved in the regulation of the GH gene (Cohen et al., 1999 & Udy et al., 1997). 
Glucocorticoid regulation of the GH gene during chicken embryonic development is 
dependent on sequences contained in the -650/+48 GH construct. Similarly, the GCRR 
alone cannot confer CORT-responsiveness to the TSHβ promoter. The TSHβ gene 
requires Pit-1 for normal expression (Haugen et al., 1996). Addition of the GCRR in 
either orientation did not confer CORT-responsiveness to the TSHβ promoter. Therefore, 
it seems that other transcription factors, binding to sites outside of the GCRR within the 
GH 5’ flanking region, are required for the CORT response. In an attempt to test this, the 
-1045 to -382 fragment of the chicken GH gene was cloned 5’ of the TSHβ promoter, 
where the distal Pit-1 site and the GCRR are maintained, and tested for CORT 
responsiveness. Again, this construct was not CORT-responsive. Transfer of -1045 to -
382 of the chicken GH promoter failed to transfer CORT responsiveness to the TSHβ 
promoter, suggesting that additional sequences of the GH gene are necessary for 
glucocorticoid regulation of the GH gene during chicken embryonic development. This 
also suggests that the underlying mechanism of glucocorticoid induction of the GH gene 
is not shared by the TSHβ gene, even though they both require Pit-1 for activation. 
Nonetheless, the GCRR was found to be orientation independent and context dependent 
in mediating glucocorticoid induction of the GH gene during chicken embryonic 
development. 
 Incubation of nuclear proteins with a probe corresponding to the proximal GCRR 
resulted in an upward shift of the probe and inclusion of unlabeled competitor DNA 
demonstrated that the shift was specific. This suggests that both the 5’ and 3’ competitors 
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interacted with protein(s) in the nuclear extract, but binding of the protein to the GCRR 
occurred along the entire length. This also demonstrates that the observed shift is a result 
from specific protein binding and not non-specific interference. Glucocorticoid induction 
of the GH gene during embryonic development involves recruitment of nuclear proteins 
to the GCRR. 
 There was a significant increase in binding to the GCRR of nuclear proteins from 
the CORT-treated cells. This leads to two possibilities: there is increased recruitment of a 
specific set of proteins from CORT-treated cells or there is recruitment of a different set 
of proteins from CORT-treated cells compared to non-treated cells. These two 
possibilities could be tested by co-immunoprecipitation. This would allow for the 
identification of proteins that interact with either GR or ETS-1. It is already known that 
GR interacts with a myriad of other proteins in almost all known mechanisms. Another 
interesting possibility would be to include nuclear extracts from cells that were pretreated 
with CHX and then treated with CORT. Differences in intensities or molecular weights of 
the shifted bands could be further explored. Regardless, glucocorticoid regulation of the 
GH gene during chicken embryonic development involves increased recruitment of 
proteins to the GCRR. 
The centered competitor corresponding to the central 34 bp of the GCRR probe 
effectively competed off nuclear protein binding. The GCRR probe was also mutated in 
the center 34 bp, and this significantly decreased protein binding. This portion of the 
GCRR contains putative binding sites for ETS-1 and GR. The flanking regions of the 
mutated probe were conserved. The 5’ flanking region contains a putative binding site for 
E47/CTCF, while the 3’ flanking region contains a putative binding site for 
 103 
 
RUSH/SMARCA3. These two proteins could be involved in glucocorticoid regulation of 
the GH gene during chicken embryonic development. CCCTC-binding factor (CTCF) is a 
zinc finger protein with almost 100% conservation of the central DNA-binding domain 
between mouse, chicken, and human. CTCF has been implicated as a transcriptional 
repressor, activator, and insulator (Phillips & Corces 2009). CTCF’s interaction with TR 
is well characterized (Arnold et al., 1996 & Lutz et al., 2003). CTCF is also known to 
interact with ER and PR (Chan & Song 2008; D’Arcy et al., 2008) However, to date, 
there is no evidence that CTCF interacts with GR. ER and GR have similar response 
elements. TR and GR do not. There is also no evidence that CTCF interacts with ETS-1. 
The GCRR contains a putative binding site for RUSH/SMARCA3 at its 3’ end, in 
addition to sites for GR and ETS-1. In this study, the chicken GH promoter was 
responsive to CORT and to a lesser extent progesterone. CORT induction of the chicken 
GH gene also required the synthesis of an intermediary protein or ongoing protein 
synthesis. The RUSH/SMARCA3 gene was induced by progesterone in rabbit uterine 
epithelial cells (Chilton & Hewetson, 2008). The RUSH/SMARCA3 gene was regulated 
by RUSHα and Sp1. RUSH/SMARCA3 was capable of specific sequence DNA binding 
and is responsible for ATP-dependent DNA unwinding. Chromosome conformation 
capture showed that RUSHα interacted with Sp1 to facilitate long range DNA looping 
necessary for gene activation. It is possible that the putative RUSH/SMARCA3 site in the 
GCRR in the chicken GH promoter is functional and necessary for DNA unwinding and 
looping for activation of the chicken GH gene. Additional studies are warranted to 




In the -1045/+48 construct, the GREF site was mutated and the CORT-response 
of the -1045/+48 GH construct was abolished. GREs seem to be degenerate. Two recent 
studies have been conducted demonstrating functional GR binding to a degenerate GRE 
and not a full-length classical GRE. The GREF identified in the GCRR, although not a 
classical GRE, can be classified as a glucocorticoid binding region, GBR. The GBR was 
identified by performing a ChIP-chip with GR (So et al., 2007). The conserved GBR 
identified is RGNACARRRWGTNCN, where R is a purine, N is any nucleotide, and W 
is an A or a T. This exact same sequence was identified on the reverse strand of the 
GCRR. Only chromatin immunoprecipitation or a positive super-shift experiment could 
definitively implicate GR binding to this site. A glucocorticoid receptor binding sequence 
(GBS) was found in the dual specificity phosphatase 1 gene promoter (DUSP1) and this 
sequence seems to be conserved across a wide range of species, such as armadillo, horse, 
cow, mouse, rat, dog and human (Tchen et al., 2010). A GBS was defined to be 
composed of the sequence GNACANNNNG. The GREF found in the GCRR of the 
chicken GH gene promoter also contains the sequence GNACANNNNG. There was also 
a good correlation between the glucocorticoid activation of the DUSP1 gene and the 
recruitment of GR to the GBS as demonstrated using ChIP (Tchen et al., 2010). The 
present study shows that the GREF site in the GCRR is essential to glucocorticoid 
regulation of the GH gene during chicken embryonic development. 
In the -1045/+48 construct, the ETS-1 site was mutated, and this mutation 
rendered the -1045/+48 GH construct unresponsive to CORT. The ETS family of 
transcription factors consists of ten family members that bind to a core sequence of 
GGAA. Five family members bind to the core sequence of CCGGAA (Thompson et al., 
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1994). It was also shown that functional redundant binding sites for all ETS-1 family 
members were more likely to occur close to the transcription start site of housekeeping 
type genes, while more specific, non-redundant functional binding sites for individual 
ETS-1 family members occurred further away from the transcription start site of more 
specialized genes (Hollenhorst et al., 2007). It is possible that an ETS-1 family member 
binds to the putative ETS-1 site in the GCRR of the chicken GH gene. ETS-1 has been 
implicated as the other required factor in the regulation of transcription of the prolactin 
gene in the rat (Bradford et al., 1997). Pit-1 is necessary, but not sufficient to direct GH 
expression in the pituitary in the rat, chicken, mouse and human. Pit-1 is also necessary, 
but not sufficient to direct prolactin expression in the pituitary in the rat. ETS-1 
physically interacts with Pit-1 at a composite cis element to direct prolactin expression. 
The phosphorylation state of Pit-1 regulates its interaction with ETS-1 (Augustijn et al., 
2002). Further, binding of Pit-1 and ETS-1 to the composite site in the proximal promoter 
of the prolactin gene is necessary for the Ras-MAPK activation of the prolactin promoter 
(Duval et al., 2003). ETS-1 has been to be involved in the regulation of the human GH 
gene. AP-1 and the ETS family member, Elk-1, were found to bind in the HS III and HS 
IV sites, respectively, of the human GH gene LCR (Jin et al., 2004). Binding of these two 
transcription factors was associated with hyperacetylation of pituitary chromatin. This 
was the first study to implicate ETS-1 or an ETS family member in GH induction. In a 
follow-up study, it was shown that Pit-1 binds to HS I and HS II of the hGH-N LCR, but 
it cannot bind to HS III alone (Yang et al., 2010). For this, it requires interaction with 
ETS-1 via Pit-1’s POU homeodomain and a composite DNA binding element. ETS-1 and 
another ETS-1 family member, Elk-1, can be co-immunoprecipitated from human 
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pituitary extracts with a Pit-1 antibody, and overexpression of Elk-1 or Pit-1 alone or 
together could increase hGH-N expression in HEK293 cells (Yang et al., 2010). This is 
the first study demonstrating that Elk-1 could induce the GH gene. Elk-1 is an immediate 
downstream target of ERK. Pharmacological inhibition of ERK signaling blocks CORT 
induction of the chicken GH gene (unpublished data). Elk-1 belongs to the ternary 
complex family (TCF), a subfamily of the Ets family (Buchwalter et al., 2004). Members 
are downstream targets of the ras-Raf-MAPK kinase signaling pathway. These two 
studies implicate ETS-1 in the regulation of the hGH-N gene. This potentially implicates 
the ETS-1 binding site in the GCRR as a necessary and essential element for 
glucocorticoid regulation of the GH gene during chicken embryonic development.  
The ETS-1 site and GREF site in the GCRR of the chicken GH gene are separated 
by only 17 bp. This begs the question, do ETS-1 and GR physically interact? The rat 
tyrosine aminotransferase (TAT) gene is induced by glucocorticoids, and it was also 
found that ETS-1 participates in this response (Espinas et al., 1994). An ETS-1 binding 
site is located in close proximity to the GR binding site. Inactivation of the ETS-1 
binding site results in a two-fold decrease of the TAT gene to GCs. The ETS-1 site is 
occupied in a GC-independent manner. Combinatorial transcription factor binding sites 
may allow for the integration of signaling from multiple external stimuli. The promoter of 
the cytochrome P450 c27 multifunctional enzyme is dexamethasone responsive. The 
promoter contains a functional GR binding site and an ETS-like site that binds ETS-2 in a 
GR-dependent manner that appears to synergistically activate the gene (Mullick et al., 
2001). GR and ETS-2 were able to co-immunoprecipitate together. The DNA binding 
domain of GR appeared to mediate the synergistic effect, while the DNA binding domain 
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of ETS-2 appeared to be a dominant negative. A fusion protein consisting of only the GR 
DNA binding domain and the ETS-2 transcriptional activation domain recapitulated the 
activation of the P450 c27 promoter, suggesting a novel synergy between these two 
proteins (Mullick et al., 2001). In the P450 c27 promoter, the GR binding site is flanked 
by two ETS like binding sites and a CTCF binding site. The sites span a region of 50 bp; 
the ETS-1 and GREF putative sites in the chicken GH promoter span a region of 34 bp. 
Additional studies are necessary to determine if GR and ETS-1 physically interact during 
CORT induction of the chicken GH gene.  
 Chromatin immunoprecipitation showed that ETS-1 is associated with the GCRR 
under basal and 1.5 h CORT-treated conditions. GR is also associated with the GCRR 
and is recruited to the proximal GCRR after 1.5 h CORT treatment. After 6 h CORT 
treatment, neither ETS-1 nor GR was associated with the GCRR. Neither of these 
proteins was associated with the distal GCRR. Chromatin immunoprecipitation is an 
elegant method to show what proteins are associated with a particular gene region under a 
set of conditions. However, the method is only successful when the protein and gene 
region of interest are known. The findings from chromatin immunoprecipitation agree 
with our previous results. CORT induced GH mRNA after 8 h of treatment, but not after 
4 h (Bossis & Porter, 2003). More recent findings from our lab show that CORT 
treatment induces GH mRNA after 1.5 h, 3 h and 6 h. GH mRNA induction stays high 
until 24 h (unpublished data). The increase of GR association with the GCRR after only 
1.5 h is supported by these findings. In the present study, it was found that ETS-1 was 
associated with the GCRR under basal conditions as well as after CORT treatment. ETS-
1 is a transcription factor that contains a nuclear localization signal (NLS) and a nuclear 
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export signal (NES) (Boulokos et al., 1989). The protein contains a serine rich region 
(SRR) that modulates the flexibility of the DNA binding domain (Lee et al., 2008).  The 
affinity for ETS-1 to bind to DNA is regulated by calcium-dependent phosphorylation 
(Pufall et al., 2005). In the present study, chromatin immunoprecipitation revealed that 
ETS-1 was associated with the GCRR and CORT treatment recruits GR to the GCRR 
after 1.5 h. This is the first study to demonstrate that GR and ETS-1 are associated with 
the promoter of the GH gene during embryonic development in the chicken.  
 E11 CEP cells were treated with CORT for 1.5 h and 6 h and fixed for later 
chromatin immunoprecipitation analysis. Likewise, e11 CEP cells were treated with 
CORT for 6 h and nuclear proteins were extracted for immediate use in EMSA. The 6 h 
chromatin immunoprecipitation data and the 6 h EMSA data do not agree. Results from 
EMSA show that protein binding to the proximal GCRR probe is increased after 6 h. 
Results from ChIP show that GR and ETS-1 association with the proximal GCRR is 
decreased after 6 h. EMSA is a technique, with which a free DNA probe is incubated 
with extracted proteins in a cell free system under optimized binding conditions. ChIP is 
a technique, with which endogenous proteins are crosslinked to the endogenous gene and 
the sample is probed with antibodies followed by PCR with primers specific to a genomic 
region to acquire a “snapshot” of the endogenous gene. There are inherent differences 
between EMSA and ChIP methodology, including the questions that the methods are able 
to answer. It is possible that another protein or protein complex is necessary to maintain 
association of ETS-1 and GR with the GCRR during glucocorticoid regulation of the GH 
gene. Further, glucocorticoid regulation of the GH gene is indirect: inclusion of CHX 
blocks CORT induction of GH mRNA. It is not known what CHX is acting on. It is 
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possible that ETS-1 and GR associate with the GCRR of the GH gene and their 
association is dependent on another protein that is synthesized at a later time in response 
to another signaling pathway. In our lab, a microarray study was conducted identifying 
genes that were regulated by glucocorticoids in the presence and absence of CHX 
(unpublished data). Inspection of the list of genes generated from this microarray may 
reveal another associated protein. Regardless, the ChIP results do agree with the mutant 
luciferase construct results. GR and ETS-1, or an ETS family member, are recruited to 
the proximal GCRR and the sites are necessary for glucocorticoid regulation of the GH 
gene during chicken embryonic development. Nonetheless, both EMSA and ChIP 
implicate binding of GR and ETS-1, or an ETS family member, to the GCRR of the GH 
gene in chickens.  
 Based on the cumulative results from the EMSA and ChIP studies, it is possible 
that GR and ETS-1 are recruited to specific sequences located in the GCRR of the 
endogenous GH gene. Once recruited, GR and ETS-1 then initiate recruitment of 
nucleosome remodeling enzymes and basal transcriptional machinery including RNA 
polymerase II. This process most likely involves cofactors and accessory proteins to form 
a bridging complex. This may also involve DNA looping to allow for the GCRR and its 
associated proteins to come into close proximity of the transcription start site. It most 
likely also requires the unwinding of nucleasomes and the formation of an “open” 
chromatin conformation that is conducive to a high rate of gene transcription. Once gene 
transcription has moved beyond the initiation phase and into the elongation phase, it is 
possible that the bridging complex, consisting of GR, ETS-1 and cofactors, falls away 
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from the gene and maximum transcription can ensue. It is known that GH transcription is 
maximal at 6 h after CORT treatment.  
This project began with two hypotheses: 1) the product of an unknown 
glucocorticoid-responsive gene induces the GH gene; 2) ligand bound GR and an 
unknown protein bind to an unknown composite element in the 5’ flanking region of the 
GH gene and induce the GH gene together. The findings of the current study did not 
outright reject either of the hypotheses, but it did identify two proteins, GR and ETS-1, 
that are involved in glucocorticoid regulation of the GH gene. We identified a functional 
degenerate GRE upstream of the GH gene in the chicken. We identified a functional 
ETS-1 site upstream of the GH gene in the chicken. We showed that each of these 
proteins bind to their own response element and not a composite element. We showed 
that ETS-1 is not a glucocorticoid regulated gene. However, it is not known whether 
ETS-1 is phosphorylated in response to glucocorticoids. Further, it is unknown whether 
bridging complexes or accessory factors are necessary for glucocorticoid induction of the 
GH gene. We also do not know the target of CHX. CHX inhibits protein synthesis and we 
do not know if glucocorticoid induction of the GH gene is dependent on a protein with a 
high turnover rate. This hypothesis is supported by the CHX data.  
Glucocorticoids play an important role in the maturation of the lungs, intestine 
and pituitary. In each of these systems, GR, although an inducing factor, does not act 
alone. In the lung, glucocorticoids induce surfactant protein with the aid of Hsp90 and 
p23 (Grad et al., 2006). The present study shows that GR and ETS-1 act together to 
induce the GH gene. The intestine is similar to the pituitary in that many different cell 
types secrete specialized enzymes necessary for digestion. Glucocorticoids are necessary 
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for the differentiation of these cell types (Lebenthal & Lebenthal, 1999). Clearly, 
glucocorticoids are necessary for life because of its role in the development of many 
organs.  
 Collectively, these results suggest that ETS-1 or an ETS family member is 
associated with its response element located at -1014 to -1009 upstream from the chicken 
GH gene under basal conditions and CORT treated conditions. GR is also associated with 
its response element located at -995 to -985, and upon CORT treatment, GR recruitment 
is increased. Both cis-acting elements are required for glucocorticoid induction of the GH 
gene during chicken embryonic development. Additional elements contained in the -650 
to +48 region, such as Pit-1, are necessary for glucocorticoid regulation of the GH gene 
during chicken embryonic development. Finally, upon CORT treatment, RNA 
polymerase II (RNA Pol II) is recruited to the transcription start site located at -56 bp. 
These findings are summarized in a model (Fig. 22). In conclusion, glucocorticoid 
regulation of the GH gene during chicken embryonic development requires cis-acting 
elements located between -1018 and -985 bp upstream from the transcription start site 
and the trans-activating factors likely include GR and belong to the ETS family.   
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Chapter 3: Conclusion & Future Directions 
 
Summary  
 A region spanning -1727/+48 of the chicken GH gene was cloned into a luciferase 
reporter construct. This GH construct was responsive to CORT, and inclusion of CHX 
blocked the CORT induction of luciferase mRNA. The transcription start site of the 
endogenous GH gene was found to be 56 bp upstream from the start codon. These 
findings, taken together, indicate that the -1727/+48 GH construct would serve as an 
appropriate model for future studies of glucocorticoid regulation of the GH gene during 
chicken embryonic development. Through deletion analysis of the GH construct, a non-
classical glucocorticoid responsive region (GCRR) of the chicken GH gene was 
identified and characterized. The GCRR was 90 base-pairs long and occurs 1 kb upstream 
of the transcriptional start site. The GCRR contained putative binding sites for ETS-1, 
GREF, CTCF and RUSH/SMARCA3. The GCRR was found to be orientation-
independent, but context-dependent. However, the GCRR cannot confer glucocorticoid 
responsiveness to the TSHβ promoter in a luciferase assay. The GCRR was able to bind 
nuclear proteins in an EMSA, as opposed to a probe that corresponds to exon 3 or a distal 
portion of the GH gene (-1566 to -1467), and in a CORT-regulated manner. The observed 
shift was competed off with a centered competitor that spans the ETS-1 and GREF sites. 
Use of a mutated probe, where the central portion of the probe spanning the putative 
ETS-1 and GREF sites was mutated, resulted in significantly reduced binding. Mutation 
of the putative ETS-1 site or the GREF site in the -1045/+48 GH construct resulted in 
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loss of CORT-responsiveness. Through chromatin immunoprecipitation, it was found that 
ETS-1 was associated with the GCRR in the endogenous GH gene under both basal and 
CORT treated conditions and GR is recruited to the GCRR after 90 m of CORT 
treatment. But both of these factors were no longer associated with the endogenous GH 
gene after 6 h. Collectively, these studies demonstrate that glucocorticoid induction of the 
GH gene during chicken embryonic development involves GR and ETS-1 binding to a 
response element approximately 1 kb upstream from the start codon. 
Future Directions 
 
The present study has identified cis-acting elements required for glucocorticoid 
regulation of the GH gene during chicken embryonic development. This study has not 
positively implicated a trans-activating factor necessary for the glucocorticoid regulation. 
Potential candidates include members of the ETS-1 family. Chromatin 
immunoprecipitation has shown that both ETS-1 and GR are recruited to the GCRR in 
e11 pituitary cells. Successful knockdown of ETS-1 or an ETS-1 family member would 
definitively implicate the trans-acting factor in glucocorticoid regulation of the GH gene 
during chicken embryonic development. This could be accomplished using several 
techniques.  
One way to determine the function of a gene is to investigate the molecular and 
physiological effects when the gene has been inactivated or “knocked down”. This can be 
accomplished through the use of small interfering RNAs or siRNA (Elbashir et al., 2001). 
siRNA has been routinely used for the past decade. RNA that is 20 to 22 bp in length is 
engineered to be specific to the mRNA of interest. The cells are transfected with the 
siRNA. The siRNA binds to its complementary mRNA. This signals a degradation 
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pathway to the cell and the target mRNA is degraded. It is typical to use a set of 3 to 5 
slightly different siRNAs to accomplish a knockdown of 50% or more. Knockdown of 
ETS-1 in e11 pituitary cells could be accomplished using commercially available siRNAs 
and then using FACS for GFP to sort only the transfected cells. Then, GH mRNA could 
be measured in the sorted cells in the context of knockdown of ETS-1. In our model 
system, cell sorting is necessary because the transfection efficiency of e11 chicken 
embryonic pituitary cells is prohibitively low. The transfection efficiency of cell lines is 
typically in the range of 75% to 95%. In our lab, the observed transfection efficiency of 
chicken embryonic pituitary cells using a GFP expression plasmid and FACS was in the 
range of 5 to 20% (Ellestad et al., 2009). A recent study demonstrated that the cellular 
uptake of siRNA could be enhanced by using cell penetrating peptides (Meade & Dowdy, 
2008). The cell membrane is largely impenetrable. This presents an obstacle to 
effectively delivering siRNA into the cell. Cell penetrating peptides are a class of small 
cationic peptides 10 to 30 amino acids in length. These charged peptides interact with the 
anionic cell membrane, are endocytosed and then escape the vesicles into the cytoplasm 
through an unknown mechanism (Meade & Dowdy, 2008).  Packaging of siRNA 
molecules with the cell penetrating peptides markedly increased the delivery. 
Knockdown via siRNA could also be accomplished by infecting e11 chicken embryonic 
pituitary cells with siRNA that is driven by a replication competent virus. Evaluation of 
the effects of knockdown of ETS-1 or another candidate on the glucocorticoid regulation 
of the GH gene during chicken embryonic development using siRNA would require cell 
sorting of transfected cells or infection of the siRNA by a replication competent virus. 
Conditionally replicating adenoviruses can be engineered to encode short-hairpin RNAs 
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to knock-down a gene target (Carette et al., 2004). Short hairpin RNAs require a cellular 
processing step, but act via a similar mechanism as siRNA to knockdown its gene target 
(Paddison et al., 2002). Conditionally replicating viruses encoding shRNAs allow for a 
more efficient delivery of the interfering RNA. This approach could circumvent our 
problem of low transfection efficiency of primary chicken embryonic pituitary cells. 
Definitive knockdown of ETS-1 could positively implicate ETS-1 as a necessary factor in 
glucocorticoid regulation of the GH gene during embryonic development in the chicken. 
 RNA interference is typically used in vitro at the cell culture or tissue culture 
level. To explore the effects of the knockdown of ETS-1 or another candidate involved in 
glucocorticoid regulation of the GH gene at the organism or whole body level, a 
transgenic chicken could be engineered. Two approaches using transgenics could be 
attempted: pituitary-specific deletion of the ETS-1 gene or another suitable candidate or 
mutation of the GCRR in the GH gene in the pituitary only. Multiple studies have been 
conducted systematically knocking out members of the ETS family in mice (Bartel et al., 
2000). Some ETS family members are necessary for life, as evidenced with the PU.1 
knockout and its role in hematopoiesis. The PU.1 knockout is embryonic lethal (Scott et 
al., 1994) or post-natal lethal (McKercher et al., 1996). But two different ETS-1 knockout 
mouse models were viable, fertile and exhibited 50% neonatal lethality (Barton et al., 
2000) or viable and fertile (Bories et al., 1995). The ETS-1 knockout mouse models had 
defects in T cell and B cell maturation and responsivity.  To date, ETS-1 has not been 
knocked out specifically in the pituitary. Recent advances have allowed for the 
engineering of transgenic chickens. An attempt to make a transgenic chicken using a 
lenti-viral vector targeted to the germ line proved to be quite successful (McGrew et al., 
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2004). Ten founder cockerels were able to transmit the lenti-viral vector to 4% to 45% of 
their offspring. The study also demonstrated successful transmission to the G2 generation. 
For the past 20 years, groups have been attempting to make transgenic chickens with 
varying success. Previous attempts at making a transgenic chicken using avian retro-
viruses, replication-competent vectors derived from avian leucosis virus (ALV) resulted 
in an extremely low transfer frequency: 1% of hatched males were germline transgenic 
(Salter & Crittendon, 1989, Bosselman et al., 1989, Rapp et al., 2003). The most 
appealing aspect of the use of lentiviral retroviruses is the fact that they can infect non-
dividing cells (Naldini et al., 1996).  It is also possible to achieve tissue-specific knock-
outs in mammals using the lenti-viral system (Lois et al., 2002). Engineering of a lenti-
viral vector for knock-out of ETS-1 in only the pituitary may be possible in the future. 
This would allow for the investigation of ETS-1 in glucocorticoid regulation of the GH 
gene during anterior pituitary gland differentiation in the embryonic chicken.  
Additionally, it might be advantageous to engineer the chicken GH gene to contain a 
mutated GCRR in the 5’ flanking region and explore the ramifications. This would 
circumvent the necessity for positively identifying the correct trans-activating factor prior 
to exploring the mutant phenotype. The present study has made great strides in the 
characterization of glucocorticoid regulation of the GH gene during embryonic 
development in the chicken, and future studies using more sophisticated methods, such as 
siRNA and transgenics, in an attempt to knockdown candidate trans-activating factors or 






 Glucocorticoid regulation of the GH gene during chicken embryonic development 
requires on-going protein synthesis or an intermediary protein. Positive identification of 
the intermediary protein may be aided by identifying glucocorticoid-regulated cis-acting 
elements. A cis-acting element located 1 kb upstream from the transcription start site at -
1045 to -954 was found to be necessary in CORT induction of the GH gene during 
chicken embryonic development. The cis-acting element or GCRR contains putative 
binding sites for ETS-1 and GREF. ETS-1 was associated with the GCRR, and GR was 
recruited to the GCRR upon glucocorticoid treatment. We conclude that GR and ETS-1 
or an ETS family member bind to the GCRR in a glucocorticoid-regulated manner as part 
of the mechanism underlying glucocorticoid induction of GH gene expression during 
chicken embryonic development. 
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Appendix A:  
The -1467/+48 FireflyLluciferase Plasmid Is Not Responsive to Other Treatments. 
 
The -1467/+48 GH construct was not CORT-responsive, and a probe 
corresponding to -1566 to -1467 of the GH gene did not bind nuclear proteins in a gel 
shift assay. Additional experiments were conducted to investigate why the -1467/+48 GH 
construct is not CORT-responsive. 
Using a transcription factor search engine, a Sp1 site was identified at -1472 to -
1467 of the chicken GH gene. WP-631, an inhibitor of Sp1, was used to determine if this 
site was functional (Appendix A, Fig. 1A). E11 pituitary cells were transfected with the -
1496/+48, -1467/+48, -1398/+48 or Basic plasmids, allowed to recover overnight and 
then treated with vehicle or WP-631 for 1 h. CORT (100 nM) was added to appropriate 
wells, and then the cells were lysed for luciferase activity 24 h later. The -1496/+48 and -
1398/+48 were again CORT-responsive and the -1467/+48 plasmid remained 
unresponsive. Pre-treatment with the Sp-1 inhibitor, WP-631, had no effect on the 
CORT-responsiveness and did not affect the basal activity of the -1467/+48 plasmid.  
CORT induction of the GH gene can also be blocked by inclusion of histone 
deacetylase inhibitors, such as trichostatin A (TSA) and HC toxin (HCT) (unpublished 
results). Therefore, e11 pituitary cells were transfected with either the -1496/+48, -
1477/+48, -1467/+48, -1430/+48, -382/+48 or Basic plasmids. The cells were pretreated 
with TSA or HCT for 90 m before the addition of CORT to appropriate wells (Appendix 
A, Fig. 1B). The cells were lysed 24 h later and luciferase activity was determined. The -
1496/+48, -1477/+48, and -1430/+48 plasmids were CORT responsive. The -1467/+48 






resulted in a global repression of luciferase activity of all of the plasmids. The plasmids 
remained non-responsive to CORT in the presence of the HDAC inhibitors. This 
experiment warrants replication.  
The -1467/+48 plasmid contains a putative CREB (cAMP-responsive element 
binding protein) site; it is possible that cAMP-regulated pathways need to be activated 
first in order for the -1467/+48 plasmid to be CORT responsive (Appendix A, Fig. 2A). 
E11 pituitary cells were transfected with either the -1496/+48, -1467/+48, -1430/+48 or 
Basic plasmids. The next day, the transfected cells were pretreated with IBMX and 
forskolin (FSK) for 1 h before the addition of CORT. The cells were lysed for 
determination of luciferase activity 24 h later. CORT induced the -1496/+48 and -
1430/+48 plasmids, regardless of IBMX and FSK pretreatment. IBMX and FSK 
treatment alone induced a 2-fold increase in luciferase activity from the -1430/+48 
plasmid. The -1467/+48 plasmid remained unresponsive to all treatments.  
The CORT induction of the GH gene also involves kinase signaling pathways, 
such as Ras and MAPK (Bossis et al., 2003 & unpublished results). Therefore, e11 
pituitary cells were transfected with either the Basic or the -1467/+48 plasmids and then 
pre-treated with the pathway inhibitors: U00126, PD098059 or manumycin for 90 m 
prior to CORT treatment (Appendix A, Fig. 2B). Neither the -1467/+48 or Basic 
plasmids were CORT responsive and the pathway inhibitors had no effect.  
Additionally, an experiment was conducted where both circular plasmids and 
linearized constructs were transfected into e11 pituitary cells and tested for luciferase 









regardless of the configuration of the plasmid. However, the -1467/+48 remained 
unresponsive to CORT, regardless of the configuration of the plasmid. 
Originally, the -1727/+48 and the -1467/+48 constructs were cloned directionally 
with an XhoI site at the 5’ end. All additional constructs were cloned non-directionally 
using HindIII sites at each end. Therefore, it is possible that the restriction site used in 
cloning introduced an artifact that interfered with the luciferase activity. The -1467/+48 
plasmid was re-cloned non-directionally using the HindIII site (Appendix A, Fig. 3B). 
However, this did not restore CORT responsiveness.  
Attempts at characterizing the -1467/+48 GH construct were unsuccessful. 
Therefore, one additional deletion construct was made, -1462/+48 and tested in e11 
chicken embryonic pituitary cells (Appendix A, Fig 4). All constructs were responsive to 
CORT treatment except for the -1467/+48 and the -1462/+48 constructs. This suggests 
that the lack of a CORT response by the -1467/+48 construct may be due to the presence 
of a repressor element that only functions when elements further upstream are deleted. 
In summary, the -1467/+48 GH construct is not responsive to CORT, kinase 
pathway inhibitors, or cAMP-pathway inhibitors. Inclusion of an inhibitor to Sp1 did not 
block the CORT response of the -1477/+48 GH construct and did not alter the non-
activity of the -1467/+48 GH constructs. Changing the restriction enzyme site for cloning 
or using a linearized plasmid also did not have an effect. One additional construct, -
1462/+48, was made and this, too, was not CORT-responsive. These results suggest that 
the lack of a CORT response by the -1467/+48 GH construct is due to the presence of a 
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